

CURRICULUM VITAE

William D. Dupont, Ph.D.

April 11, 2019

PRESENT POSITION

Professor of Biostatistics and Preventive Medicine

Address: Department of Biostatistics
Vanderbilt University School of Medicine
Suite 1100 – Room 11119
2525 West End Avenue
Nashville, Tennessee 37203-8354

Telephone: (615) 343-4100
Facsimile: (615) 343-4924
E-Mail: william.dupont@vanderbilt.edu

Web Page: <http://biostat.mc.vanderbilt.edu/WilliamDupont>

EDUCATION

McGill University, Montreal, QC, Canada
B.Sc. 1969 — Mathematics

McGill University, Montreal, QC, Canada
M.Sc. 1971 — Mathematics

The Johns Hopkins University, Baltimore, MD
Ph.D. 1977 — Biostatistics

Continuing Education — Short Courses Attended

1. The Statistical Analysis of Failure Time Data. Given by J.D. Kalbfleisch and R.L. Prentice. Toronto, ON, 1981.
2. Advanced Statistical Methods in Epidemiology. Given by N.E. Breslow, N.E. Day, D. Claton, and J. Kaldor. University of Washington, Seattle, WA, 1988.
3. Short Course on Meta-Analysis. Given by T. Chalmers and I. Olkin. Sponsored by the Centers for Disease Control. Atlanta, GA, 1993.
4. Statistical Methods for Genetic Epidemiology. Given by Robert C. Elston and Daniel J. Schaid. Biometric Society Spring Meetings. Cleveland, OH, 1994.

5. Visualizing Data with Trellis Graphics. Given by Stephen Kaluzny. The International Biometric Society (ENAR) Meeting. Memphis, TN, March, 1997.
6. Writing Mixed models and SAS PROC MIXED for Repeated Measures and Random Effects Data. Given by R. D. Wolfinger. The International Biometric Society (ENAR) Meeting. Memphis, TN, 1997.
7. Statistical Analysis with Missing Data. Given by R.J.A. Little and T.E. Raghunathan. The International Biometric Society (ENAR) Meeting. Pittsburgh, PA, 2004.
8. Modeling and Analysis of Categorical Data with Overdispersion. Given by Jorge Morel and Nagaraj Neerchal. Joint Statistical Meetings. Toronto, Ontario Canada. 2004.
9. Power and Sample Size Analysis Using New SAS/STAT Software. Given by John Casteloe. Joint Statistical Meetings. Toronto, Ontario Canada. 2004.
10. Statistical Genetics. Given by Kenneth Lange, Janet Sinsheimer and Eric Sobel. Joint Statistical Meetings. Salt Lake City, Utah. 2007.
11. Absolute Risk Prediction. Given by Mitchell H. Gail and Ruth Pfeiffer, Joint Statistical Meetings. Washington, DC. 2009.
12. Multilevel and Mixed Models in Stata. Given by Roberto G. Gutierrez. Joint Statistical Meetings. Washington, DC. 2009.
13. Causal Inference. Given by Miguel Hernan and James Robins. Joint Statistical Meetings. Vancouver, BC, Canada. 2010.
14. Statistical Methods for Genome-wide Association Studies. Given by Jennifer Clarke and Adrian Dobra. Joint Statistical Meetings. Vancouver, BC, Canada. 2010.
15. Sensitivity Analysis with Missing Data: Statistical Methods and Case Studies. Given by Joseph Hogan and Daniel Scharfstein. ENAR spring meetings. Washington, DC. 2012.
16. Statistical Genetic and Genomic Analysis of Complex Traits with GWAS and Next Generation Sequencing Data. Given by Hongyu Zhao and Fei Zou. ENAR spring meetings. Austin TX, 2016.
17. Interactive Data Visualizations in R with shiny and ggplot2. Given by Garrett Grolemond. ENAR spring meetings. Austin TX, 2016.
18. A New Paradigm for Finding the Subset of Patients who Benefit from a Test Treatment. Given by Richard Simon and Noah Simon. ENAR spring meetings. Austin TX, 2016.
19. Quantile Regression for Survival Analysis. Given by Limin Peng. ENAR spring meetings. Austin TX, 2016.
20. Machine Learning, Artificial Intelligence, and Precision Medicine. Given by Haoda Fu & Yufeng Liu. ENAR spring meetings. Washington DC, 2017.
21. Statistical Evaluation of Medical Risk Prediction Models in the Presence of Competing Risks. Given by Michael W. Kattan & Thomas A. Gerds. ENAR spring meetings. Washington DC, 2017.
22. Statistical Analysis of RNA Sequencing Data. Given by Mingyao Li. ENAR spring meetings. Washington DC, 2017.

23. Data-driven Modeling Techniques for Medical Decision Making. Given by Madhu Mazumdar. ENAR spring meetings. Washington DC, 2017.
24. Statistical Issues in Comparative Effectiveness Research. Given by Sharon-Lise Normand. ENAR spring meetings. Washington DC, 2017.

ACADEMIC APPOINTMENTS

1976 – 1977	Lecturer University of Maryland in Baltimore County
1977 – 1985	Assistant Professor of Preventive Medicine (Biostatistics) Vanderbilt University School of Medicine
1986 – 1992	Associate Professor of Preventive Medicine (Biostatistics with tenure) Vanderbilt University School of Medicine
1987 – 1988	Acting Director, Division of Biostatistics Vanderbilt University School of Medicine
1989 – 2003	Director, Division of Biostatistics Vanderbilt University School of Medicine
1992 – present	Professor of Preventive Medicine (Biostatistics) Vanderbilt University School of Medicine
1994 – 1997	Director, Biostatistics/Data Management Shared Resource Vanderbilt Cancer Center Vanderbilt University School of Medicine
2003 – present	Professor of Biostatistics Vanderbilt University School of Medicine
2010 – 2019	Vice-Chair for Academic Affairs, Department of Biostatistics Vanderbilt University School of Medicine

PROFESSIONAL ORGANIZATIONS

1. *American Statistical Association*, 1975 – present
2. *Biometric Society*, 1974 – present
3. *Society for Clinical Trials*, 1980 – ??
4. *Society for Epidemiologic Research*, 1985 – 1994
5. *American Association for the Advancement of Science*, 1987 – 2003

PROFESSIONAL ACTIVITIES

Intramural

1. Member of the Graduate Faculty Delegate Assembly at Vanderbilt University, 1979 – 1982.
2. Member of the Clinical Research Center Advisory Committee, 1985 – 1989.
3. Member of the Medical Center Quality Care Committee, 1987 – 1989.
4. Member of the Cancer Prevention Research Program, Vanderbilt-Ingram Cancer Center, 1998 - Present.
5. Member of the Bioinformatics Faculty Recruitment Task Force, 1999 - 2000.
6. Member of the Faculty Appointments and Promotions Committee of School of Medicine of Vanderbilt University School of Medicine, 2003 – 2009.
7. Member of the Medical Center Tenure Review Committee, 2010-2012.
8. Member of the Biostatistics Department Awards Committee 2014 – present.
9. Member of the Graduate Students Award Committee. 2015 – present.

Extramural

1. Has refereed papers for the following journals:
 - i) *American Statistician*
 - ii) *American Journal of Epidemiology*
 - iii) *American Journal of Obstetrics and Gynecology*
 - iv) *American Journal of Public Health*
 - v) *Breast*
 - vi) *Biometrical Journal*
 - vii) *Biometrics*
 - viii) *Cancer*
 - ix) *Cancer Causes and Control*
 - x) *Cancer Research*
 - xi) *Clinical Pharmacology & Therapeutics*
 - xii) *Computer Methods and Programs in Biomedicine*
 - xiii) *Controlled Clinical Trials*
 - xiv) *Drug Safety*
 - xv) *European Journal of Cancer and Clinical Oncology*
 - xvi) *Human Pathology*
 - xvii) *International Journal of Cancer*
 - xviii) *International Journal of Epidemiology*
 - xix) *JAMA Oncology*
 - xx) *Journal of Andrology*
 - xxi) *Journal of the National Cancer Institute*

- xxii) *Journal of Wildlife Management*
- xxiii) *Menopausal Medicine*
- xxiv) *New England Journal of Medicine*
- xxv) *PLOS ONE*
- xxvi) *Radiation Effects Research Foundation Technical Reports*
- xxvii) *Southern Medical Journal*
- xxviii) *Stata Journal*
- xxix) *Statistics in Medicine*

2. Co-Chairman, local arrangements committee, 1983 Spring meetings of the Biometric Society (Eastern North American Region) in Nashville.
3. Member of the National Cancer Institute's Breast Cancer Working Group, 1988 – 1990.
4. American Cancer Society referee for postdoctoral fellowship applications, 1989.
5. Participated in the NCI Breast Cancer Progress Review Group, Baltimore, MD, 1997.
6. Member of the American Joint Committee on Cancer: Statistics Committee, 2000 – 2001.

Membership in Data Monitoring Boards

1. Effect of Polyunsaturated Lecithin on Liver Fibrosis. Department of Veterans Affairs Cooperative Study #391, Baltimore, MD, 1994 –2000.
2. Surgical Infection Society (SIS) multicenter study of duration of antibiotics for intra-abdominal infection. Principal Investigator: Robert G. Sawyer, MD, University of Virginia. NIH grant # R01 GM 081510.

Editorial Advisory Boards

1. *Cancer*, 1995 – 2003
2. *The Breast*, 1996 – 2008

Associate Editorships

1. *Stata Journal*, 2004 – present

Membership in NIH Study Sections And Review Committees

1. *Epidemiology and Disease Control Study Section-2*
 - i) October 12 – 14, 1988
 - ii) February 5 – 8, 1991
 - iii) October 19 – 21, 1992
 - iv) February 3 – 5, 1993
 - v) March 18 – 19, 1996
2. *Epidemiology and Disease Control Study Section-1*

- i) August 9, 1988
 - ii) December 15, 1988
 - iii) March 29, 1989
3. *Subcommittee E- Cancer Epidemiology, Prevention and Control*
- i) August 4, 2004
 - ii) September 29, 2004
4. *Geriatrics and Rehabilitation Study Section*
- i) February 21, 1995
5. *Special Study Section for Small Grants in Epidemiology*
- i) April 19, 1989
 - ii) August 8, 1989
 - iii) December 4, 1990
6. *RFP Reviews*
- i) June 28, 1990, NIAID
 - ii) April 12, 1992, NICHD
7. *Special Review or Study Section*
- i) April 21, 1988
 - ii) November 16, 1988
 - iii) April 28, 1994
 - iv) January 13, 1998
8. *NCI Special Emphasis Panel*
- i) November 2002, Community Clinical Oncology Program Grant Review
 - iii) July 2003, Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
 - iv) October 2013, Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (UM1)
 - v) April 2014, NCI Community Oncology Research Program (NCORP) Community Sites (UM1)
9. *NCI Initial Review Group: Subcommittee H – Clinical Groups*
- i) October 26-28, 2003, Review of the Gynecologic Oncology Group grant application
 - ii) October 13,14, 2008 Review of Cancer and Leukemia Group B (CALGB) grant application.

10. *Clinical Oncology Study Section*
 - i) October 11-12, 2010.
11. NCI Community Oncology Research Program
 - i) April 24-24, 2014. Telephone review of grants in response to RFA-CA-13-013.
12. *Site Visit Committees*
 - i) March 20 – 21, 1991, Harvard University, NCI Special Review.
 - ii) January 29, 1993, University of Texas, EDC-2.
 - iii) November 16 – 18, 1994, Columbia University, NCI, Breast Cancer and the Environment of Long Island.
 - iv) October 22 – 24, 1995, Harvard University, NCI Special Review.
 - v) October 6 – 8, 1997, Johns Hopkins University, NCI Review Panel.
 - vi) March 11-13, 1998, Cleveland Clinic Cancer Center, NCI Review Panel.
 - vii) May 20-22, 1998, Fred Hutchinson Cancer Research Center, NCI Review Panel.
 - viii) June 17, 1998, Johns Hopkins University, NCI Review Panel (telephone review of revised application)
 - ix) September 15-16, 2003, Roswell Park Cancer Institute, Buffalo, New York: NCI Review Panel for the Gynecologic Oncology Group Statistical and Data Center.

Special Awards or Recognition for Professional Activities

- 2003 Earnest W. Goodpasture Award – with David L. Page for collaborative studies that address important biological problems and their role in disease pathogenesis
- 2009 Selected as a fellow of the American Statistical Association.
- 2013 Selected as a scholar in the Vanderbilt Center for Health Services Research.

TEACHING

1. At Vanderbilt

Courses Given

- i.) Medical Statistics (PM 502): Taught 1978 – 1980.
- ii.) The Analysis of Failure Time Data (BIOS 294): Taught 1980.
- iii.) Biostatistics 2 (PUBH 514-5509) Developed course on generalized linear models, survival analysis and analysis of variance given in the M.P.H program, 1997, 1999, and 2001 – 2017.

- iv.) Biostatistics 1 (PUBH 514-5502) Course on basic concepts and methods of biostatistics given in the M.P.H. program, 2009.
- v.) Introduction to Study Design (BIOS 6306) Introduction to study design: Taught 2016.

Lectures and Seminars

- i.) Lectures in Epidemiology for Engineering Students (EWRE 327): A series of 3 lectures given in 1978 – 1982.
- ii.) The Design and Analysis of Electrocardiographic Experiments: Clinical Pharmacology seminar, 1978.
- vi.) Statistical Power and Sample Size Calculations: Department of Surgery seminar, 1981.
- vii.) Analyzing Data from Clinical Trials: Clinical Pharmacology seminar, 1981.
- viii.) Principles of Public Health and Preventive Medicine (PM 503): Gave lectures on case control studies and on clinical trials. Led discussion groups on these and other topics, 1984.
- ix.) Cancer, Basic Concepts (Path 5210): Gave introductory lecture on cancer epidemiology, 1984.
- x.) Fundamentals of Clinical Trials (MED 533): Gave lecture on hypothesis testing, statistical inference, and sample size calculations for clinical trials, 1984.
- xi.) Principles of Epidemiology, Biostatistics and Preventive Medicine (PM 501): Organized a three-week section on cancer epidemiology. Gave lectures on population based studies, case-control studies, and cohort studies. Introduced concepts of hypothesis testing, statistical power, and sample size determination, 1985 – 1987, 1999. Gave lectures on clinical trials, 1988, 1995 – 1997; statistical inference, 1988, 1989, 1996, and 1997; screening for cancer, 1990. Led group sessions on these topics, 1991 – 1998, 1999, 2002.
- xii.) Epidemiology of Breast Cancer: Obstetrics and Gynecology Grand Rounds given with D.L. Page, 1986. Broadcast on the VMT television network and published on video cassette.
- xiii.) Risk Factors for Breast Cancer in Women with Proliferative Breast Disease: Preventive Medicine seminar, 1986.
- xiv.) Sample Size Estimation in Matched Case-Control Studies: Preventive Medicine seminar, 1987.
- xv.) Controversies in Clinical Trials: Cardiology seminar, 1987.
- xvi.) Introduction to Survival Analysis: Center for Fertility and Reproductive Research Seminar, 1988.
- xvii.) Does Replacement Estrogen Increase the Risk of Breast Cancer?: Preventive Medicine Research Conference, 1989.

- xviii.) What Are the Frontiers of Research in Benign Breast Disease?: Preventive Medicine Research Conference, 1989.
- xix.) Some Common Statistical Errors in the Medical Literature: Clinical Pathology Conference, 1990.
- xx.) Model for Continuous Data with Constant Variance: Seminar on Chapter 3 from McCullagh and Nelder, *Generalized Linear Models*, given to the Middle Tennessee Chapter of the American Statistical Association, 1990.
- xxi.) Models for Survival Data: Seminar on Chapter 13 from McCullagh and Nelder, *Generalized Linear Models*, given to the Middle Tennessee Chapter of the American Statistical Association, 1990.
- xxii.) Two-Stage Linear Models: Seminar on Chapter 6 from Crowder and Hand, *Analysis of Repeated Measures*, given to Middle Tennessee Chapter of the American Statistical Association, 1991.
- xxiii.) Breast Cancer Risk Associated with Proliferative Breast Disease and Atypical Hyperplasia: Preventive Medicine Research Conference, 1992.
- xxiv.) An Overview of Meta-Analysis: Methods for Reviewing Medical Literature: Preventive Medicine Research Conference, 1993.
- xxv.) Understanding (explaining) the Relationship Between Relative and Absolute Risk: Preventive Medicine Research Conference, 1995.
- xxvi.) Lies, Damn Lies, and Statistics: Pediatric Neonatology Seminar, 1995.
- xxvii.) Hormone Replacement Therapy and Breast Cancer: Breast Cancer Training Grant (L.M. Matrisian, P.I.), December 1995.
- xxviii.) The Pros and Cons of Hormonal Replacement Therapy: Preventive Medicine Seminar, November 1997.
- xxix.) Estrogen Replacement Therapy in Women with a History of Proliferative Breast Disease: Preventive Medicine Conference, December 1997.
- xxx.) A Brief Introduction to Logistic Regression and Survival Analysis: Can You Survive This Regression? Pulmonary Medicine Seminar, March 1999.
- xxxi.) Transforming Growth Factor- β Type II Receptors and Breast Cancer Risk in Women with Mammary Epithelial Hyperplasia: Preventive Medicine Seminar, January, 2000, also given to the Vanderbilt Program in Human Genetics, February 2000.
- xxxii.) How to calculate sample size and statistical power using the PS software program. GCRG Research Skills Workshop, May 2002.
- xxxiii.) TGF- β 1 T29 \rightarrow C Polymorphism and Breast Cancer Risk in Women with and without Proliferative Disease: VICC Breast Cancer Program Seminar, October 2003.
- xxxiv.) How to use the sample size software PS for survival analyses and complex study designs. GCRC Research Skills Workshop, October 2003.

- xxxv.) Using Density Distribution Sunflower Plots for the Display of Dense Bivariate Data. Biostatistics Seminar. August 2004.
- xxxvi.) Introduction to Logistic Regression. GCRC Research Skills Workshop Series. November, 2004.
- xxxvii.) Some considerations for using PS sample size software. M.S. Biostatistician's Workshop, March, 2006
- xxxviii.) The Conditionality Principle and 2x2 Contingency Tables: Some Thoughts on the Foundations of Statistical Inference: Part I. Biostatistics Seminar given with Leena Choi, April 2006.
- xxxix.) The Conditionality Principle and 2x2 Contingency Tables: Some Thoughts on the Foundations of Statistical Inference: Part II. Biostatistics Seminar given with Leena Choi, April 2006.
- xl.) How to do Power & Sample Size Calculation - Part 1. GCRC Research Skills Workshop Series. October, 2007.
- xli.) How to do Power & Sample Size Calculation - Part 2. GCRC Research Skills Workshop Series. October, 2007.
- xlii.) Introduction to Power and Sample Size Calculations. Department of Pathology Seminar. November 2007.
- xliii.) Response Feature (Two-Stage) Analysis of Longitudinal Data: A simple approach to analyzing complicated data. Biostatistics Seminar, April 2010
- xliv.) Response Feature (Two-Stage) Analysis of Longitudinal Data: A simple approach to analyzing complicated data. Vanderbilt Neurocardiology Rounds, May 2010.
- xlv.) Lasso Regression: Some thoughts and simulation studies: M.S. Biostatisticians journal club. September 2012.
- xlvi.) Grant Writing as a Collaborator or Principal Investigator: Lecture in SPR.GS.BIOS.352 Statistical Collaboration in Health Sciences II. April 2013, February 2014, October 2014, October 2015.
- xlvii.) Relative and Absolute Risks: Explaining the practical implications of research findings to patients and clinicians. Symposium on Personalized Risk Prediction. April 2013.
- xlviii.) Stopping Rules in Clinical Trials and Approaches to Phase II Studies. Presentation to the Vanderbilt Neurocardiology Study Group. June 2013.
- xlix.) Introduction to Clinical Trials. Lecture given as part of the graduate program in cellular and molecular pathology course 351 entitled "Cellular and Molecular Basis of Disease." November 2013.
- l.) Building your Dossier for Promotion and Tenure. Seminar given to the Newman Society, February 2014.
- li.) Statistical Issues in Grant Writing: Introduction to Power & Sample Size Calculations. Lecture given in PUBH 5539 course entitled "Grant Writing and Scientific Communication." May 2014.

- lii.) Introduction to Causal Inference. Seminar given to the Center for Asthma Research, December, 2014
- liii.) Introduction to Causal Inference, Part 2. Seminar given to the Center for Asthma Research, January, 2015
- liv.) Introduction to Marginal Structural Models: How to analyze longitudinal data when previous treatments affect subsequent covariates which in turn influence subsequent treatment. Seminar given to the Center for Asthma Research, October, 2015
- lv.) Introduction to Causal Inference, Part 1. Seminar given to the graduate students in biostatistics, January 2016.
- lvi.) Introduction to Causal Inference, Part 2. Seminar given to the graduate students in biostatistics, January 2016.
- lvii.) Introduction to Marginal Structural Models: Seminar given to the Department of Biostatistics, January, 2016, to the Center for Health Services Research, May 2016.

2. At Other Universities

Courses Given

- i) Introduction to Statistics for Social Scientists. (Math 0121, University of Maryland): Taught 1976, 1977.
- ii) Ideas in Mathematics (Math 0100, University of Maryland): Taught 1977.

Lectures and Seminars

- iii) Comparing Low Mortality Rates in Longitudinal Censored Observational Data. Seminar given at Johns Hopkins University in 1979.
- iv) The Analysis of Cohort Data in Ecologic Statistics. Seminar given at Utah State University and Johns Hopkins University in 1980.
- v) Principles of Data Management for Ecologists. Seminar given at Utah State University, 1981.
- vi) A Stochastic Catch-Effort Method for Estimating Animal Abundance. Seminar given at Johns Hopkins University in 1982 and at the Savannah River Ecology Laboratory in 1985.
- vii) Risk Factors for Breast Cancer in Women with Proliferative Breast Disease. Seminar given at the Université de Montpellier, France, and at the Certificat International des Maladies du Sein, Paris, France, 1986.
- viii) Power Calculations for Matched Case-Control Studies. Seminar given at Johns Hopkins University in 1987.
- ix) Premalignant Markers of Increased Breast Cancer Risk. Seminar given at the National Institute of Environmental Health Sciences, 1992.

- x) Understanding (explaining) the Relationship Between Relative and Absolute Risk. Seminar given at the Memorial Sloan-Kettering Cancer Institute, New York, NY, 1995.
- xi) The Relationship of Proliferative Changes and Fibroadenoma to Breast Cancer Risk. Pathology Grand Rounds. St. Barnabas Medical Center, Livingston, NJ, 1995.
- xii) L'Oestrogénothérapie Substitutive et le Risque de Cancer du Sein. Seminar given at the Institut Paoli-Calmettes, Marseille, France, 1995.
- xiii) Les Mastoses Prolifératives, les Adénofibrome et le Risque de Cancer du Sein. Seminar given at the Institut Paoli-Calmettes, Marseille, France, 1995.
- xiv) Benign Breast Diseases, Hormonal Replacement Therapy and Breast Cancer Risk. Centro de Estudos Olinto de Oliverira Instituto Fernandis Figueira Rio de Janeiro, Brazil, June 1995.
- xv) Effects of Protein Phosphatase 2A Subunit Gene haplotypes and Proliferative Breast Disease on Breast Cancer Risk. Mayo Clinic, Rochester MN, May 2009.
- xvi) Identifying a Breast Cancer Genetic Locus at NCOA7 through a Multi-stage Association Study. Biostatistics Division, Washington University School of Medicine, St. Louis MO, October, 2011.
- xvii) Introduction to Longitudinal Data Analysis. Guest lecture given as part of Course 321: Applied Epidemiologic Methods in Regression I: Binary Data. Meharry Medical College, Nashville TN, November 2012.

Membership in Ph.D. Thesis Committees and Student and Faculty Mentoring

- L. Renee Bailey, PhD. Pathology, 1996 – 1998
 PhD thesis “Genetic Susceptibility and Carcinogen Metabolism in Breast Cancer Molecular Epidemiology”
 Role: PhD Advisory Committee member
- S. Trent Rosenbloom, MD, MPH. Informatics, 2001 – 2002
 MPH thesis “Patterns of Serum Magnesium Testing at Vanderbilt University Medical Center”
 Role: MPH mentor
- Brian Yaspan, MPH, Cancer Biology, 2005 – 2008
 PhD Thesis “Genetic Predisposition to Prostate Cancer: The Contribution of the HPCX locus and TGFBI gene”
 Role: PhD Advisory Committee member
- Kecia N. Carroll, MD, MPH, FAAP, Pediatrics, 2007 – 2015
 Role: Mentoring Committee member
- Pingsheng Wu, PhD. Biostatistics, 2007 – present
 Role: Mentoring Committee member

Vincent Agboto, PhD. Biostatistics, Meharry Medical College 2008 – 2014
Role: Mentoring Committee member

Emily Rose Holzinger, Human Genetics, 2010 – present
Role: PhD Advisory Committee member

Renee W. Ward, M.D. Obstetrics and Gynecology, 2014 – present
Role: Mentoring Committee member

Nathaniel David Mercaldo, Biostatistics, 2014 – present
Role: PhD Advisory Committee member

Derek Smith, Biostatistics, 2015 – present
Role: PhD Advisory Committee member

RESEARCH PROGRAM

Current Research at Vanderbilt

1. Conducting epidemiologic studies of genetic, molecular and histologic risk factors for breast cancer (with D.L. Page, J.R. Smith, F.F. Parl and M.E. Sanders).
2. Working with T.V. Hartert (Allergy / Pulmonary and Critical Care Medicine) on studies on risk factors for asthma in children.
3. Working with D. Robertson (Clinical Pharmacology Division/Medicine) on studies of Autonomic Cardiovascular Regulation.
4. Working with W.A. Ray on studies of pharmacoepidemiology involving opioids, proton pump inhibitors in warfarin users, and other drugs.

Grants Received as Principal Investigator

1. An Epidemiologic Study of Breast Cancer Risk Factors. NCI grant #RO1 CA 28223-01, 1980 – 81. \$39,773 awarded for direct costs.
2. The Effect of Lobular Atrophy on Breast Cancer Risk in Women Who Have Undergone Benign Breast Biopsies. Biomedical Research Support Grant #RR-05424, 1981. \$2,500 awarded.
3. Epidemiology of Breast Cancer Risk After Fibroadenoma. NCI grant #RO1 CA31698, 1982 – 1985. \$379,280 awarded for direct costs in 1982 – 85.
4. Breast Cancer Risk Associated with Fibroadenomas and Other Histologic and Epidemiologic Risk Factors. Biomedical Research Support Grant #RR-05424-24, 1985. \$5,806 awarded.
5. Lopressor in Myocardial Infarction Trial. 1986 – 1988 Contract from CIBA-GEIGY Corporation for \$55,514 to build and analyze a patient database from a multi-center clinical trial.

6. Breast Cancer Risk After Atrophic or Apocrine Changes. NCI grant #RO1-CA40517, 1986 – 1989. \$600,752 awarded for 1986 – 1989.
7. Breast Cancer in Women with Proliferative Breast Disease. NCI grant #RO1-CA46492, 1988 – 1991. \$454,638 awarded for 1988 – 1991.
8. Epidemiology of Molecular Risk Factors for Breast Cancer. NCI grant #RO1- CA50468, 1990 – 2012. \$10,451,779 awarded.

Grants Received as Local Principal Investigator or Project Leader

1. SPORE in Breast Cancer. NCI grant #P50 CA098131, 2003-20010. Project Co-leader for Project 4: “Molecular Epidemiology of Proliferative Breast Disease”.
2. Mayo Clinic Breast Cancer SPORE. NCI grant P50 CA116201. Local PI. 2011 – 2016.
3. Mammographic Breast Density in a Cohort of Medically Underserved Women. NIH grant W81XWH-10-1-0993. Site PI. 2010 – 2015

Grant Support Received as Co-Investigator

4. SCOR in Hypertension, NHLBI grant #HL-14192, 1977 – 1995.
5. Risk Associated with the Diagnosis of Non-Invasive Mammary Carcinoma and Pre-Cancerous Mammary Hyperplasias. NCI grant #CB74098, 1977 – 1980.
6. Professional Oncology Education Program, NCI grant #2 R25 CA 19429-09, 1984 – 1987.
7. Efficacy of Cold Adapted Influenza Vaccine. NIAID Contract #N01-AI-52593, 1985 – 1991.
8. Cardiopulmonary Effects of Ibuprofen in Human Sepsis. NHLBI grant #RO1-HL-43167, 1990 – 1995.
9. SCOR in Acute Lung Injury, 5P50 grant #HL19153, 1995 –1998.
10. Mechanisms of Post Bone Marrow Transplantation Lung Injury. NIH/NHLB(HL) grant #1R01 HL55198, 1995 – 1999.
11. Patient Care Provider Order Entry with Tactical Support. NIH grant #1R01 LM06226-01A1, 1997 – 2000.
12. Etiology of Early Breast Malignancy. NCI grant #R01-CA72025, 1996 – 2000.
13. Autonomic Cardiovascular Regulation. NIH grant #1P01-HL56693, 1997 – 2010.
14. Chemotherapy Toxicity: Reduction in the Urea Cycle Support. NIH/NCI grant #5R01-CA92313, 2001 – 2006.
15. SPORE in Breast Cancer. NCI grant #P50 CA098131, 2003-20010. Project Co-leader for Project 4: “Molecular Epidemiology of Proliferative Breast Disease”.
16. The Vanderbilt Institute for Clinical and Translational Research (VICTR) NCRR grant #UL1 RR024975, 2007 – 2008.

17. Maternal and Infant Effects of Treated and Untreated Depression during Pregnancy. NIMH grant #R03 MH077902, 2007 – 2008.
18. Dietary Antioxidants and Incidence of Adult-onset Asthma. NIAID grant #R02 AI50884, 2007 – 2008.
19. MCC and VICC Partners in Eliminating Cancer Disparities. NCI grant #U54 CA091405, 2007 – 2008.
20. Asthma Disparities in Cohorts at Risk for Morbidity. NHLBI grant #U01 HL072471, 2006 – 2008.
21. The Nashville Breast Health Study. NCI grant #R01 CA100374, 2007 – 2009.
22. Dopamine-B-Hydroxylase in Human Cardiovascular Control. NHLBI grant # R01 HL071784, 2008 – 2010.
23. Targeting peripheral-derived regulatory T cells as a means of enhancing immune responses directed against prostate cancer. DOD grant PC140122 / W81XWH-15-1, 2015 – 2018.
24. Autoimmune Basis for Postural Tachycardia Syndrome. NHLBI grant R56HL128393, 2015 – 2016.
25. Pregnancy Folate Status & Early Childhood Respiratory & Atopic Disease Outcomes. NHLBI grant R01HL109977-05. 2011 – 2016.
- 26.** (W.D. Dupont local site PI) Mayo Clinic Breast Cancer SPORE. NCI grant P50 CA116201. 2011 – 2016.
27. Autonomic Cardiovascular Regulation. NHLBI grant P01 HL056693. 1998 – 2017.
28. Host and Viral Determinants of Infant and Childhood Allergy and Asthma. NHLBI grant U19 AI095227. 2011 – 2016.
29. Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users NHLBI grant R01HL114518. 2013 – 2017.
- ^{30.} 31. Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome
32. 5R01 HL102387-05 Garland (PI) 09/01/2010-06/30/2015
33. The major goal of this project is to mechanistically understand the regulation and effects of the hormones that control sodium handling in postural tachycardia syndrome (POTS), in order to develop rational treatment approaches to improve heart rate control and decrease the disability in POTS. Role: Business Manager
- ^{34.} 35. W81XWH-10-1-0993 Dupont (site PI) 09/01/2010-006/30/15
36. (NCE)
37. Mammographic Breast Density in a Cohort of Medically Underserved Women
38. The major goal of this project is to partner faculty from Vanderbilt University Medical Center who have expertise in breast cancer research and faculty from Meharry Medical College who have strong ties with minority and medically underserved communities to develop an outstanding breast cancer research program which will provide formal training to junior MMC faculty in cancer biology, behavioral sciences, biostatistics and molecular epidemiology. Role: Site PI
- ^{39.} 40. 1RC4 MH092755-01 Wu (PI) 09/27/2010-08/31/2013
41. Statistical methods for comparative treatment effectiveness using claims data

42. The major goal of this project is to address an important gap in the current analytical approach to medication comparative effectiveness, and to enhance and improve the quality of observational comparative effectiveness research. Role: Co-Investigator
- 43.
44. 5R01 CA050468-20 Dupont (PI) 05/01/1990-01/31/2014
45. Epidemiology of Molecular Risk Factors for Breast Cancer
46. The major goals of this project are to evaluate the combined influence on breast cancer risk of benign breast lesions and 424 single nucleotide polymorphisms (SNPs) from 86 candidate genes involved in estrogen biosynthesis, function and oxidative metabolism. Cross-sectional analyses will also be performed that examine how specific genotypes are correlated with different types of benign breast disease. Role: Principal Investigator
- 47.
48. 5R01 HS018454-03 Hartert (PI) 09/30/2009-07/31/2013
49. Tools to Reduce Infant RSV Morbidity and Asthma: Use, Adherence and Effectiveness
50. The objectives of this study are to determine the disparities in use, adherence and “real world”
51. effectiveness and whether there are any important long-term protective effects on preventing diseases such as asthma, of a medication to prevent severe infant viral respiratory tract infections from a virus known as RSV.
52. Role: Co-Investigator
- 53.
- 54.
55. 5P50 CA098131-10 Arteaga (PI) 09/11/2008-05/31/2014
56. SPORE in Breast Cancer
57. Specific Aim 1: To study molecular and histologic markers of breast cancer risk in women with benign proliferative breast disease. Specific Aim 2: To study the effect of epithelial hyperplasia lacking atypia on breast cancer risk among African-Americans. Specific Aim 3: To conduct a series of nested case-control studies on the women involved. Specific Aim 4: This project will permit the combination of modern methods in molecular biology, pathology and epidemiology to assess potentially powerful new markers of breast cancer prognosis, and my lead to important advances in the prevention and treatment of the disease.
58. Role: Project Director
- 59.
- 60.
61. 5U54 CA091405-10 Moses (PI) 08/01/2009-07/31/2012
62. The goal of this pilot project is to investigate the relation of vitamin D and genotypes affecting vitamin D signaling to the prevalence of high risk mammographic findings in a predominately African American population. It is a component of the Meharry Medical College/Vanderbilt Ingram Cancer Center Partnership to Eliminate Cancer Disparities. Role: Co-Investigator
- 63.
- 64.
65. VUMC 38980-R Dupont (PI) 07/01/2011-01/03/2014
66. Development of Risk Predictor Model for Women with Atypical Hyperplasia
67. Data and specimens from the Nashville Breast Cohort will be used for test set analyses of studies that are being done by Dr. Hartmann at the Mayo Clinic. Role: Principal Investigator
- 68.
- 69.
70. 5R01 HL071784-09 Robertson (PI) 02/01/2003-03/31/2014
71. Dopamine-B-Hydroxylase in Human Cardiovascular Control
72. This study will assess whether impaired sodium handling by renal dopamine contributes to the hypovolemia of postural tachycardia syndrome (POTS). We seek to determine the role of dopamine in POTS. Investigations of POTS patients and normal controls will be undertaken with careful control of sodium intake and monitoring of urinary sodium and dopamine excretion. Role: Co-Investigator
- 73.
- 74.

75. 5U54 NS065736-05 Robertson (PI) 08/15/2009-07/31/2014
76. Autonomic Rare Diseases Clinical Research Consortium
77. The objective is to study autonomic disorders so that we can develop novel therapies aimed not only at improving quality of life, but also altering the course of disease. Role: Co-Investigator
78.
79.
80. 5R01HD074584-06 (Ray) 01/01/13 - 12/31/17 1.08 calendar months
81. NIH/NICHD \$296,559
82. Prescribed Opioid Safety in Children
83. This project we will conduct a large retrospective cohort study in an estimated 500,000 Tennessee Medicaid children 2-17 years of age with 1,000,000 filled opioid prescriptions and 1400 confirmed cases of opioid toxicity.
84.
85. 6R01HL114518-04 (Ray) 06/01/13 - 05/31/17 1.20 calendar months
86. NIH/NHLBI \$360,721
87. Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users
88. This proposal will study whether proton-pump inhibitors reduce the risk of gastroduodenal bleeding in patients taking oral anticoagulants.
89.
90. 6R01HS022093-02 (Wu) 09/30/13-09/29/17 0.60 calendar months
91. AHRQ \$456,704
92. Real-World Patient Responsiveness and Safety of Long-Acting Beta Agonists in Asthma
93. This project is of critical importance as it addresses comparative effectiveness and safety concerns in asthma pharmacotherapy. It will inform and empower physicians, patients, and healthcare policy makers providing timely knowledge in how, when, and to whom to provide or avoid LABA containing therapies. Such knowledge will have widespread public health impact in asthma disease management.
94.
95. 6P01HL56693-20 (Robertson, Jr.) 05/01/12 – 04/30/17 1.20 calendar months
96. Autonomic Cardiovascular Regulation 1,256,074
97. The major goal of this project is to achieve better understanding of how the brain exerts control over the autonomic nervous system and how the latter expresses that control onto effector tissues, through the integrating theme of autonomic cardiovascular regulation.
98.
99. 6U54NS065736-08 (Robertson, Jr.) 09/30/15-06/30/19 0.90 calendar months
100. NINDS \$1,060,864
101. Autonomic Rare Diseases Clinical Research Consortium
102. Autonomic disorders cause loss of regulation of the heart, blood vessels, stomach, bowel and bladder.
103. Affected patients frequently have palpitations or lose consciousness, and some have a rapidly fatal course.
104. The Autonomic Consortium proposes to join with patient support groups to harness the knowledge and
105. energies of physicians and investigators in the major centers where these patients are cared for, so that they

106. can discover ways to treat and to cure these diseases.
- 107.
108. VUMC61226(R56HL128393) (Robertson, Jr.) 09/04/15 – 12/31/17 0.60 calendar months
109. University of Oklahoma Health Center/NIH \$120,360
110. Autoimmune Basis for Postural Tachycardia Syndrome
111. Vanderbilt's role in the NIH project "Autoimmune basis for POTS: longitudinal and mechanistic studies" will be to recruit patients with postural tachycardia syndrome (POTS) and control subjects, perform the physiology studies and human phenotyping, and perform the longitudinal follow-up for that portion of Specific Aim #1. The Vanderbilt Autonomic Dysfunction Center specializes in disorders such as Postural Tachycardia Syndrome (POTS). We have significant clinical research experience in human physiological studies including autonomic function testing, and orthostatic posture studies. We also have significant experience in recruiting and studying healthy subjects as "control subjects" for this patient population. Role: Co-Investigator
- 112.

PUBLICATIONS AND PRESENTATIONS

Articles in Refereed Journals

1. Latham RH, Kaiser AB, **Dupont WD**, and Dan BB: Chronic pulmonary histoplasmosis following the excavation of a bird roost. *Am J Med*, 1980; 68(4):504-8.
2. **Dupont WD**, Rogers LW, VanderZwaag R, and Page DL: The epidemiologic study of anatomic markers for increased risk of mammary cancer. *Pathol Res Pract*, 1980; 166:471-80.
3. Kampmeier RH, Sweeney A, Quinn RW, Lefkowitz LB, and **Dupont WD**: Survey of 251 patients with acute syphilis treated in the collaborative penicillin study of 1943 to 1950. *Sex Transm Dis*, 1981; 8:266-79.
4. Dean RH, Kieffer RW, Smith BM, Oates JA, Nadeau JH, Hollifield JW, and **Dupont WD**: Renovascular hypertension: Anatomic and renal function changes during therapy. *Arch Surg*, 1981; 116:1408-15
5. Brorson L, Reece S, **Dupont W**, Woosley RL, Shand D, and Smith R: Effects of concentration and steric configuration of propranolol on AV conduction and ventricular repolarization in the dog. *J Cardiovasc Pharmacol*, 1981; 3:692-703.
6. Page DL, **Dupont WD**, Rogers LW, and Landenberger M: Intraductal carcinoma of the breast. Follow-up after biopsy only. *Cancer*, 1982; 49:751-8.
7. Parl FF and **Dupont WD**: A retrospective cohort study of histologic risk factors in breast cancer patients. *Cancer*, 1982; 50:2410-6.
8. **Dupont WD**: Sequential stopping rules and sequentially adjusted P values: Does one require the other? *Controlled Clin Trials*, 1983; 4:3-10.
9. **Dupont WD**: Rejoinder: statistical inference from trials with sequential stopping rules. *Controlled Clin Trials*, 1983; 4:27-33.
10. **Dupont WD**: A stochastic catch-effort method for estimating animal abundance. *Biometrics*, 1983; 39:1021-33.

11. Dean RH, Kreuger TC, Whiteneck JM, **Dupont B**, Foster JH, Smith BM, Hollifield JW, and Oates JA: Operative management of renovascular hypertension: results after a follow-up of fifteen to twenty-three years. *J Vasc Surg*, 1984; 1:234-42.
12. Halter SA, Fraker LD, Parmenter M, and **Dupont WD**: Carcinoembryonic antigen expression and patient survival in carcinoma of the breast. *Oncology*, 1984; 41:297-302.
13. Dean RH, Keyser JE, **Dupont WD**, Nadeau JH, and Meacham PW: Aortic and renal vascular disease: Factors affecting the value of combined procedures. *Ann Surg*, 1984; 200:336-44. PMID: PMC1250483.
14. Parl FF, Schmidt BP, **Dupont WD**, and Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, auxiliary node metastasis and histopathologic grading. *Cancer*, 1984; 54:2237-42.
15. **Dupont WD** and Page DL: Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med*, 1985; 312:146-51.
16. Page DL, **Dupont WD**, Rogers LW, and Rados MS: Atypical hyperplastic lesions of the female breast: A long-term follow-up study. *Cancer*, 1985; 55:2698-2708.
17. Dean RH, Englund R, **Dupont WD**, Plummer WD, Pierce R, and Ezell C: Retrieval of renal function by revascularization: study of preoperative outcome predictors. *Ann Surg*, 1985; 202:367-75. PMID: PMC1250921.
18. **Dupont WD**: Randomized versus historical clinical trials: Are the benefits worth the cost? *Am J Epidemiol*, 1985; 122:940-46.
19. Greer JP, Kinney MC, Cousar JB, Flexner JM, **Dupont WD**, Graber SE, Greco FA, Collins RD, and Stein RS: Lymphocyte-depleted Hodgkin's disease: a clinicopathologic review of 25 patients. *Am J Med*, 1986; 81:208-14.
20. Page DL, **Dupont WD**, and Rogers LW: Breast cancer risk of lobular-based hyperplasia after biopsy: 'Ductal' pattern lesions. *Cancer Detect Prev*, 1986; 9:441-8.
21. **Dupont WD**: Sensitivity of Fisher's exact test to minor perturbations in 2 x 2 contingency tables. *Stat Med*, 1986; 5:629-35.
22. Page DL and **Dupont WD**: Are breast cysts a premalignant marker? *Eur J Cancer and Clin Oncol*, 1986; 22:635-6.
23. **Dupont WD** and Page DL: Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. *Am J Epidemiol*, 1987; 125:769-79.
24. Gordon L, Wood AJJ, Koshakji RP, Wilkinson GR, **Dupont WD**, and Wood M: Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. *Anesthesiology*, 1987; 67:225-30.
25. Page DL, **Dupont WD**, and Rogers LW: Ductal involvement by cells of atypical lobular hyperplasia in the breast: A long-term follow-up study of cancer risk. *Hum Pathol*, 1988; 19:201-7.
26. Kronenberg MW, Uetrecht JP, **Dupont WD**, Davis MH, Phelan BK, and Friesinger GC: Intrinsic left ventricular contractility in normal subjects. *Am J Cardiol*, 1988; 61:621-7.

27. Page DL and **Dupont WD**: Histopathologic risk factors for breast cancer in women with benign breast disease. *Semin Surg Oncol*, 1988; 4:213-7.
28. **Dupont WD**: Power calculations for matched case-control studies. *Biometrics*, 1988; 44:1157-68.
29. Kossoy LR, Hill GA, Herbert CM, Brodie BL, Dalglish CS, **Dupont WD**, and Wentz AC: Therapeutic donor insemination: The impact of insemination timing with the aid of a urinary luteinizing hormone immunoassay. *Fertil Steril*, 1988 49:1026-9.
30. King JC, Haugh CJ, **Dupont WD**, Wright PF, and Edwards KM: Laboratory and epidemiologic assessments of a recent influenza B outbreak. *J Med Virol*, 1988; 25:361-8.
31. **Dupont WD** and Page DL: Cancer risk in benign breast disease. *Reviews on Endocrine-Related Cancer*, 1988; 32:5-9.
32. **Dupont WD**, Page DL, Rogers LR, and Parl FF: Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. *Cancer*, 1989; 63:948-57.
33. Antman EM, **Dupont WD**, Bonalsky J, et al.: Early treatment with intravenous metoprolol for suspected acute myocardial infarction: A phase IV United States trial. *Int J Cardiol*, 1989; 23:185-97.
34. **Dupont WD** and Page DL: Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. *Hum Pathol*, 1989; 20:723-5.
35. **Dupont WD**: Converting relative risks to absolute risks: A graphical approach. *Stat Med*, 1989; 8:641-51.
36. Tham KT, **Dupont WD**, Page DL, Gray GF, and Rogers LW: Micro-papillary hyperplasia with atypical features in female breasts, resembling gynecomastia. *Progress in Surgical Pathology*, 1989; 10:101-9.
37. Jensen RA, Page DL, **Dupont WD**, and Rogers LW: Invasive breast cancer risk in women with sclerosing adenosis. *Cancer*, 1989; 64:1977-83.
38. Parl FF, Cavener DR, and **Dupont WD**: Genomic DNA analysis of the estrogen receptor gene in breast cancer. *Breast Cancer Res Treat*, 1989; 14:57-64.
39. Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, **Dupont WD**, Hager CC, and Wright PF: Evaluation of a new highly purified pertussis vaccine in infants and children. *J Infect Dis*, 1989; 160:832-7.
40. Page DL and **Dupont WD**: New biologic prognostic factors in breast cancer: The article reviewed. *Oncology*, 1989; 3:58.
41. **Dupont WD** and Plummer WD: Power and sample size calculations: A review and computer program. *Controlled Clin Trials*, 1990; 11:116-28.
42. **Dupont WD** and Page DL: L'oestrogénothérapie substitutive accroît-elle le risque de cancer du sein? *Contraception Fertilité Sexualité*, 1990; 18:115-9.
43. Page DL and **Dupont WD**: Premalignant conditions and markers of elevated risk in the breast and their management. *Surg Clin North Am*, 1990; 70:831-51.

44. Page DL and **Dupont WD**: Anatomic markers of human premalignancy and risk of breast cancer. *Cancer*, 1990; 66:1326-35.
45. Simpson JF, Page DL, and **Dupont WD**: Apocrine adenosis — A mimic of mammary carcinoma. *Surg Pathol*, 1990; 3:289-99.
46. **Dupont WD** and Page DL: Menopausal estrogen replacement therapy and breast cancer. *Arch Intern Med*, 1991; 151:67-72.
47. Novak JM, Scribner KT, **Dupont WD**, and Smith MH: Catch-effort estimation of white-tailed deer population size. *Journal of Wildlife Management*, 1991; 55:31-8.
48. **Dupont WD**: Ethics and statistics in randomized clinical trials — comment. *Stat Science*, 1991; 6:69-71.
49. Page DL and **Dupont WD**: Histologic indicators of breast cancer risk. *Bulletin of the American College of Surgeons*, 1991; 76:16 – 23.
50. Page DL, Kidd TE, **Dupont WD**, Simpson J, and Rogers LW: Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease. *Hum Pathol*, 1991; 22:1232-9.
51. Page DL and **Dupont WD**: Proliferative breast disease: Diagnosis and implications, *Science*, 1991; 253(5022): 915-6.
52. Yaich L, **Dupont WD**, Cavener DR, and Parl FF: Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. *Cancer Res*, 1992; 52:77-83.
53. Page DL and **Dupont WD**: Benign breast disease: Indicators of increased breast cancer risk. *Cancer Detect Prev*, 1992; 16:93-7.
54. Page DL and **Dupont WD**: Indicators of increased breast cancer risk in humans. *J Cell Biochem*, 1992; 16G:175–182.
55. Page DL and **Dupont WD**: Breast cancer angio-histogenesis: Through a Narrow Window. *J Natl Cancer Inst*, 1992; 84:1850-1.
56. **Dupont WD**, Parl FF, Hartmann WH, Brinton LA, et al.: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. *Cancer*, 1993; 71:1258-65.
57. Page DL and **Dupont WD**: Anatomic indicators (histologic and cytologic) of increased breast cancer risk. *Breast Cancer Res Treat*, 1993; 28:157-66.
58. Jensen RA, **Dupont WD**, and Page DL: Diagnostic criteria and cancer risk of proliferative breast lesions. *J Cell Biochem*, 1993; 17G:59-64.
59. Edwards KM, **Dupont WD**, Westrich KM, Plummer WD, Palmer PS, and Wright PF: A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. *J Infect Dis*, 1994; 169:68-76.
60. O'Malley FP, Page DL, Nelson EH, and **Dupont WD**: Ductal carcinoma in-situ of the breast with apocrine cytology: Definition of a borderline category. *Hum Pathol*, 1994; 25:164-8.

61. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, **Dupont WD**, and Parl FF: p53 gene mutations and steroid receptor status in breast cancer: Clinicopathologic correlations and prognostic assessment. *Cancer*, 1994; 73:2147-56.
62. Dalton LW, Page DL, and **Dupont WD**: Histologic grading of breast carcinoma: A reproducibility study, *Cancer*, 1994; 73:2765-70.
63. **Dupont WD**, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr., Rados MS, and Schuyler PA: Long-term breast cancer risk in women with fibroadenoma. *N Engl J Med*, 1994; 331:10-5.
64. Simpson JF, O'Malley FP, **Dupont WD**, and Page DL: Heterogeneous expression of nm23 gene product in non-invasive breast carcinoma. *Cancer*, 1994; 73:2352-8.
65. O'Malley FP, Vnencak-Jones CL, **Dupont WD**, Parl F, Manning S, and Page DL: p53 mutations are confined to the comedo type ductal carcinoma in-situ of the breast: Immunohistochemical and sequencing data. *Lab Invest*, 1994; 71:67-72.
66. **Dupont WD**: Evidence of efficacy of mammographic screening for women in their forties. *Cancer*, 1994; 74:1204-6.
67. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, **Dupont WD**, and Parl FF: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. *J Natl Cancer Inst*, 1995; 87:446-51.
68. Page DL, **Dupont WD**, Rogers LW, Jensen RA, and Schuyler PA: Continued local recurrence of carcinoma 15 – 25 years after a diagnosis of low grade ductal carcinoma in-situ of the breast treated only by biopsy. *Cancer*, 1995; 76:1197-200.
69. Page DL, **Dupont WD**, and Jensen RA: Papillary apocrine change of the breast: Associations with atypical hyperplasia and risk of breast cancer. *Cancer Epidemiol Biomark Prev*, 1996; 5:29-32.
70. Vnencak-Jones CL, Phillips JA, Janco RL, Cohen MP, **Dupont WD**, Kazazian HH, and Rossitier JP: Analysis of factor VIII gene inversion mutations in 166 unrelated hemophilia A families: frequency and utility in genetic counseling. *Hemophilia*, 1996; 2:18-23.
71. **Dupont WD** and Plummer WD: Understanding the relationship between relative and absolute risk. *Cancer*, 1996; 77:2193-9.
72. Page DL, Salhany KE, Jensen RA, and **Dupont WD**: Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. *Cancer*, 1996; 78:258-66.
73. Carmichael LC, Dorinsky PM, Higgins SB, Bernard GR, **Dupont WD**, Swindell B, and Wheeler AP: Diagnosis and therapy of Acute Respiratory Distress Syndrome in adults: An international survey. *J Critical Care*, 1996; 11:9-18.
74. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, **Dupont WD**, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. *N Engl J Med*, 1997; 336:912-8.
75. Kasami M, Vnencak-Jones CL, Manning S, **Dupont WD**, and Page DL: Loss of heterozygosity and microsatellite instability in breast hyperplasia: No obligate correlation of these genetic alterations with subsequent malignancy. *Am J Pathol*, 1997; 150:1925-32. PMID: PMC1858322.

76. Page DL, **Dupont WD**, Holt JT, and Jensen RA: Directions and associations in premalignant breast disease: the important role of non-comedo ductal carcinoma in situ, *Endocrine-Related Cancer*, 1997; 4:105-12.
77. Page DL, Johnson JE, and **Dupont WD**: Probabilistic approach to reporting of fine-needle aspiration cytology of the breast, *Cancer (Cancer Cytopathology)*, 1997; 81:6-9.
78. Bailey LR, Roodi N, Verrier CS, Yee CJ, **Dupont WD**, and Parl FF: Breast Cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. *Cancer Res*, 1998; 58: 65-70.
79. Page DL, **Dupont WD**, Jensen RA, and Simpson JF: When and to what extent do pathologists agree?, *J Natl Cancer Inst.* 1998; 90: 88-9.
80. Kasami M, Vnencak-Jones CL, Manning S, **Dupont WD**, Jensen RA, and Page DL: Monoclonality in fibroadenomas with complex histology and phyllodal features. *Breast Cancer Res Treat*, 1998; 50: 185-91.
81. Bailey LR, Roodi N, **Dupont WD**, and Parl FF: Association of cytochrome P450 *1B1 (CYP1B1)* polymorphism with steroid *receptor* status in breast cancer. *Cancer Res*, 1998; 58: 5038-41.
82. **Dupont WD** and Plummer WD: Power and sample size calculations for studies involving linear regression. *Controlled Clin Trials*, 1998; 19: 589-601.
83. Page DL, **Dupont, WD**: Benign breast diseases and premalignant breast disease. *Arch Pathol Lab Med*, 1998; 122: 1048-50
84. **Dupont WD**, Page DL, Parl FF, Plummer WD, Schuyler PA, Kasami M, and Jensen RA: Estrogen replacement therapy in women with a history of proliferative breast disease. *Cancer*, 1999; 85: 1277-83.
85. Arons, MM, Wheeler, AP, Bernard GR, Christman BW, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson W, Wright P, **Dupont WD**, Swindell BB: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. *Crit Care Med*, 1999; 27: 699-707.
86. **Dupont, WD**, Plummer, WD: Exact confidence intervals for odds ratios from case-control studies. *Stata Technical Bulletin*. 1999; STB-52: 12-14.
87. Gobbi H, **Dupont WD**, Simpson JF, Plummer WD, Schuyler PA, Olson SJ, Arteaga CL, and Page DL: Transforming growth factor- β and breast cancer risk in women with mammary epithelial hyperplasia. *J Natl Cancer Inst.*, 1999; 91: 2096-101.
88. Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, **Dupont WD**, Blamey RW. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. *Mod Pathol*, 2000; 13(7): 730-5.
89. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, **Dupont WD**, Olson SJ, Schuyler PA, Plummer WD, and Page DL: Loss of expression of transforming growth factor β type II receptor correlates with high tumor grade in human breast in situ and invasive carcinomas. *Histopathology*, 2000; 36: 168-77.

90. Kasami M, Gobbi H, **Dupont WD**, Simpson JF, Page DL, and Vnencak-Jones CL: Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. *The Breast*, 2000; 9: 23-7.
91. Mangialardi RJ, Martin GS, Bernard GR, Wheeler AP, Christman BW, **Dupont WD**, Higgins SB, and Swindell BB: Hypoproteinemia predicts ARDS development, weight gain and death in patients with sepsis. *Crit Care Med*, 2000; 28(9): 3137-45.
92. Page DL, Jensen RA, Simpson JF, **Dupont WD**. Historical and epidemiological background of human premalignant breast disease. *J Mammary Gland Bio and Neoplasia*, 2000; 5(4): 341-9.
93. Peebles RS, Carpenter CT, **Dupont WD**, Loyd JE. Mediastinal fibrosis is associated with human leukocyte antigen-A2. *Chest*, 2000; 117(2): 482-5.
94. Carter BA, Page DL, Schuyler P, Parl FF, Simpson JF, Jensen RA, **Dupont WD**: No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. *Cancer*, 2001; 92(1); 30-6.
95. Mommers EC, Page DL, **Dupont WD**, Schuyler P, et al. Prognostic value of morphometry in patients with normal breast tissue or usual ductal hyperplasia of the breast. *Int J Cancer*, 2001; 95: 282-5.
96. Neuzil KM, **Dupont WD**, Wright PF, and Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection. *Pediatr Infect Dis J.*, 2001; 20(8); 733-40.
97. Ritchie MD, Hahn LW, Roodi N, Bailey R, **Dupont WD**, Parl FF, Moore JH: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. *Am J Hum Genet*, 2001;69:138-47. PMID: PMC1226028.
98. Martin GS, Mangialardi RJ, Wheeler AP; **Dupont WD**, Morris JA, Bernard GR: Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. *Critical Care Medicine*, 2002;30:2175-82.
99. Page DL, Schuyler PA, **Dupont WD**, Jensen RA, Plummer WD, Simpson JF: Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. *Lancet*, 2003;361:125-9.
100. **Dupont WD** and Plummer WD: Density distribution sunflower plots. *Journal of Statistical Software*, 2003; 8:(3)1-5. Posted at <http://www.jstatsoft.org/v08/i03/paper>. Accessed June 14,2011. See also *Journal of Computational and Graphical Statistics*, 2003;12:247.
101. Page DL, Marcus JN, **Dupont WD**: Premalignant lesions in hereditary breast cancer families. *Am J Oncology Review*, 2003; 2:2-3.
102. Roodi N, **Dupont WD**, Moore JH, Parl FF: Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk. *Cancer Res*, 2004; 64:1233-36.

103. Wagner C, Stone WJ, Koury MJ, **Dupont WD**, Kerine DM: S-adenosylhomocysteine is a more sensitive indicator of renal insufficiency than homocysteine. *Nutrition Res*, 2004; 24:487-94.
104. Neilson EG, Johnson KB, Rosenbloom ST, **Dupont WD**, Talbert D, Giuse DA, Kaiser A, and Miller RA for the Resource Utilization Committee: The impact of peer management on test ordering behavior. *Ann Intern Med*, 2004; 141:196-204.
105. Gobbi H, **Dupont WD**, Parl FF, Schuyler PA, Plummer WD, Olson SJ, Page DL: Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units. *Int J Cancer*, 2005; 113 (5): 857-59.
106. McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, **Dupont WD**, Page DL: Immunohistochemical Expression of Estrogen Receptor in Enlarged Lobular Units with Columnar Alteration in Benign Breast Biopsies: A Nested Case-Control Study. *Am J Surg Pathol*. 2005; 29 (1): 105 - 8.
107. Sanders ME, Schuyler PA, **Dupont WD**, Page DL: Natural history of low grade ductal carcinoma in situ in women treated by biopsy only revealed over 30 years long-term follow-up, *Cancer*, 2005; 103 (12): 2481-4.
108. Rosenbloom ST, Geissbuhler AJ, **Dupont WD**, Giuse DA, Talbert DA, Tierney WM, Plummer WD, Stead WW, Miller RA: Effect of CPOE user interface design on user-initiated access to educational and patient information during clinical care. *J Am Med Inform Assoc*, 2005; 12 (4): 458-73. PMID: PMC1174891.
109. Collier B, Diaz J, Forbes R, Morris J, May A, Guy J, Ozdas A, **Dupont W**, Jensen G: The impact of a normoglycemic management protocol on clinical outcomes in the trauma intensive care unit. *JPEN J Parenter Enteral Nutr*, 2005; 29 (5): 353 - 59.
110. **Dupont WD**, Plummer WD: Using density distribution sunflower plots to explore bivariate relationships in dense data. *Stata J*, 2005; 5(3):371 - 84.
111. McLaren BK, Smith J, Schuyler PA, **Dupont WD**, Page DL: Adenomyoepithelioma: Clinical, histologic, and immunohistologic evaluation of a series of related lesions. *Am J Surg Pathol*, 2005; 29 (10): 1294-1299.
112. Jabs K, Koury MJ, **Dupont WD**, Wagner, C: Relationship between plasma S-adenosylhomocysteine concentration and glomerular filtration rate in children. *Metabolism*, 2006; 55 (2):252-257.
113. Grijalva CG, Craig AS, **Dupont WD**, Bridges CB, Schraq, SJ, Iwane MK, Schaffner W, Edwards KM, Griffin MR: Estimating influenza hospitalizations among children. *Emerg Infect Dis*, 2006;12 (1):103-9.
114. Cohen SM, **Dupont WD**, Courey MS. Quality-of-life impact of non-neoplastic voice disorders: A meta-analysis. *Ann Otol Rhinol Laryngol*. 2006; 115 (2):128-134.
115. Sanders ME, **Dupont WD**, Schuyler PA, Simpson JF, Page DL: Interdependence of radial scar and proliferative disease with respect to invasive breast cancer risk in benign breast biopsies. *Cancer*, 2006; 106 (7): 1453–61.

116. Jensen GL, Silver HJ, Roy MA, Callahan E, Still C, **Dupont W**: Obesity is a risk factor for reporting homebound status among community dwelling older persons. *Obesity*, 2006;14 (3): 509-17.
117. McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, **Dupont WD**, Page DL: Excellent Survival, Cancer Type, and Nottingham Grade following Atypical Lobular Hyperplasia on Initial Breast Biopsy. *Cancer*, 2006;107:1227-33.
118. Cohen SM, Garrett CG, **Dupont WD**, Ossoff RH, Courey MS. Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. *Ann Otol Rhinol Laryngol*. 2006; 115(8):581-6.
119. Grijalva CG, Weinberg GA, Bennett NM, Staat MA, Craig AS, **Dupont WD**, et al. Estimating the undetected burden of influenza hospitalizations in children. *Epidemiol Infect* 2007; 135 (6): 951-8.
120. Yaspan BL, Breyer JP, Cai Q, Dai Q, Elmore JB, Amundson I, Bradley KM, Shu XO, Gao YT, **Dupont WD**, Zheng W, Smith JR. Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk. *Cancer Res* 2007;67(12):5673-82. PMID: PMC2805128.
121. Carroll KN, Gebretsadik T, Griffin MR, **Dupont WD**, Mitchel EF, Wu P, et al. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. *Pediatrics* 2007;119(6):1104-12.
122. Fasig JH, **Dupont WD**, Olson SJ, Lafleur BJ, Cates JM: Steroid Hormone Receptor and COX-2 Expression in Chordoma. *Am J Clin Pathol*. 2007;128(3):375-81.
123. Enriquez R, Griffin MR, Carroll KN, Wu P, Cooper WO, Gebretsadik T, **Dupont WD**, Mitchel EF, Hartert TV. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. *J Allergy Clin Immunol*. 2007; 120(3):625-30.
124. Denny JC, Frederick VA, **Dupont WD**, Neilson EG: Increased Hospital Mortality in Patients with Bedside Hippus. *Am J Med*. 2008; 121: 239-245. PMID: 18328309.
125. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, **Dupont WD**, Scheinin M, Wood AJJ, Stein CM. Ethnic and genetic determinants of cardiovascular response to the selective alpha(2)-adrenoceptor agonist dexmedetomidine. *Hypertension*. 2008; 51(2): 406-411. PMID: 18071056. Free full text
126. Fasig JH, **Dupont WD**, LaFleur BJ, Olson SJ, Cates JMM. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. *Neuropathol Appl Neurobiol*. 2008; 34(1): 95-104. PMID: 17973908.
127. Hartert TV, Deng X, Hartman TJ, Wen W, Yang G, Gao Y-T, Jin M, Bai C, Gross M, Roberts LJ, Sheller JR, Christman J, **Dupont W**, Griffin M, Shu XO. The Shanghai Women's Asthma and Allergy Study: Objectives, Design, and Recruitment Results. *Am J Epidemiol*. 2008; 167(11): 1387-96. PMID: PMC2430736.
128. Cates JMM, **Dupont WD**, Barnes JW, Edmunds HS, Fasig JH, Olson SJ, Black CC. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. *Appl Immunohistochem Mol Morphol* 2008; 16(11): 251-62. PMID: 18301244.

129. Carroll KN, Gebretsadik T, Griffin MR, Wu P, **Dupont WD**, Mitchel EF, Enriquez R, Hartert TV. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. *Pediatrics* 2008; 122(1): 58-64. PMID: PMC2655142.
130. Kurnik D, Friedman EA, Muszkat M, Sofowora GG, Xie HG, **Dupont WD**, Wood AJ, Michael Stein C. Genetic variants in the alpha2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses. *Pharmacogenet Genomics*. 2008;18(9):743-50. PMID: PMC2689621.
131. Boulos FI, **Dupont WD**, Simpson JF, Schuyler PA, Sanders ME, Freudenthal ME, Page DL. Histologic Associations and Long-Term Cancer Risk in Columnar Cell Lesions of the Breast: A Retrospective Cohort and a Nested Case-Control Study. *Cancer*. 2008; 113(9): 2415-21. PMID: PMC3121952.
132. Wu P, **Dupont WD**, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, Hartert TV. Evidence of a causal role of winter virus infection during infancy on early childhood asthma. *Am J Respir Crit Care Med*. 2008; 178(11): 1123-9. PMID: PMC2588491.
133. Breyer JP, Sanders ME, Airey DC, Cai Q, Yaspan BL, Schuyler PA, Dai Q, Boulos F, Olivares MG, Bradley KM, Gao YT, Page DL, **Dupont WD**, Zheng W, Smith JR. Heritable Variation of *ERBB2* and Breast Cancer Risk. *Cancer Epidemiol Biomarkers Prev*. 2009; 18(4): 1252-1258. PMID: PMC2730036.
134. Carroll KN, Wu P, Gebretsadik T, Griffin MR, **Dupont WD**, Mitchel EF, Hartert TV. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. *J Allergy Clin Immunol* 2009; 123(5): 1055-61. PMID: PMC2703291.
135. Carroll KN, Wu P, Gebretsadik T, Griffin MR, **Dupont WD**, Mitchel EF, Hartert TV. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. *J Allergy Clin Immunol* 2009; 123(4): 964-6. PMID: PMC2707077.
136. Valet RS, **Dupont WD**, Mitchel EF Hartert TV. Beta-agonist use as an indicator of change in asthma control during pregnancy. *Ann Allergy Asthma Immunol*. 2009; 102(4): 352-3. PMID: 19441610. PMID:19441610.
137. Breyer, JP, McReynolds KM, Yaspan BL, Bradley KM, **Dupont WD**, and Smith JR. Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes. *Cancer Epidemiol Biomarkers Prev*. 2009; **18(7)**: 2137-44. PMID: PMC2813685.
138. Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, **Dupont WD**, Robertson D. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. *Circulation*, 2009; **120(9)**: 725-34. PMID: PMC2758650.
139. Dorjgochoo, T., Noel, F., Deschamps, M. M., Theodore, H., **Dupont, W.**, Wright, P. E., Fitzgerald, D. W., Vermund, S. H., and Pape, J. W. Risk Factors for HIV Infection Among Haitian Adolescents and Young Adults Seeking Counseling and Testing in Port-au-Prince. *JAIDS-J Acq Imm Def* 2009; **52**: 498-508. PMID: PMC3196358
140. **Dupont WD**, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Sanders ME, Page DL, Smith JR. Effect of protein phosphatase 2A subunit gene haplotype and proliferative

- breast disease on breast cancer risk. *Cancer*. 2010; **116(1)**:8–19. PMID: PMC2807897
141. Lewis TJ, **Dupont WD**, Egan KM, Jones CD, Disher AC, Riddle WR, Fair AM. The "Got D'ViBE?" Study: An Inter-Institutional Project Assessing Vitamin D and Mammographic Breast Density. *J Health Care Poor U*. 2010;**21**:17-25. PMID: PMC2930256
 142. Kohli U, Muszkat M, Sofowora GG, Harris PA, Friedman EA, **Dupont WD**, Scheinin M, Wood AJJ, Stein CM, Kurnik D. Effects of variation in the human alpha(2A)- and alpha(2C)-adrenoceptor genes on cognitive tasks and pain perception. *Eur J Pain* 2010;**14**:154-9. PMID: PMC2815116
 143. Cates JMM, Friedman DB, Seeley EH, **Dupont WD**, Schwartz HS, Holt GE, Caprioli RM, Young PP. Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. *Int J Exp Patho*. 2010;**91**:335-49. PMID: 2962892.
 144. Deng XQ, Gebretsadik T, Jin ML, Gao YT, Bai CX, Christman JW, Wen WQ, **Dupont WD**, Plummer D, Stephens J, Shu XO, Hartert TV. Development of a nomogram for identification of asthma among adults in epidemiologic studies. *Ann Allergy Asthma Immunol*. 2010; **105(3)**: 203-10. PMID: PMC2930896
 145. Rosenbloom ST, McGregor TL, Chen Q, An AQ, Hsu S, **Dupont WD**. Specialized Pediatric Growth Charts For Electronic Health Record Systems: the example of Down syndrome. *AMIA Annu Symp Proc*. 2010; **2010**:687-91. PMID: PMC3041286.
 146. McClintock-Treep SA, Briggs RC, Shults KF, Flye-Blakemore LA, Mosse CA, Jagasia MH, Shinar AA, **Dupont WD**, Stelzer GT, Head DR. Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow. *Am J Clin Pathol*. 2011;**135(3)**:380-5. PMID: 21350091 Free full text.
 147. Mustafa HI, Garland EM, Biaggioni I, Black BK, **Dupont WD**, Robertson D, Raj SR. Abnormalities of angiotensin regulation in postural tachycardia syndrome. *Heart Rhythm*. 2011;**8(3)**:422-8. PMID: PMC3050076.
 148. Ramirez NE, Zhang ZH, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li ZZ, **Dupont WD**, Zijlstra A, Zutter MM. The $\alpha_2\beta_1$ integrin is a metastasis suppressor in mouse models and human cancer. *J Clin Invest*. 2011;**121(1)**:226-37. PMID: PMC3007139.
 149. Miller EK, Williams JV, Gebretsadik T, Carroll KN, **Dupont WD**, Mohamed YA, Morin LL, Heil L, Minton PA, Woodward K, Liu ZW, Hartert TV. Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness. *J Allergy Clin Immunol*. 2011;**127(4)**:883-91. PMID: PMC3070861.
 150. Kauffmann RM, Norris PR, Jenkins JM, **Dupont WD**, Torres RE, Blume JD, Dossett LA, Hranjec T, Sawyer RG, May AK. Trends in Estradiol During Critical Illness Are Associated with Mortality Independent of Admission Estradiol. *J Am Coll Surg*. 2011;**212(4)**:703-12. PMID: PMC3073628.
 151. Higginbotham KSP, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Freudenthal MG, Trentham-Dietz A, Newcomb PA, Sanders ME, Page DL, Parl FF, Egan KM, **Dupont WD** Smith JR. A multi-stage association study identifies a breast cancer locus at NCOA7. *Cancer Res* 2011;**71(11)**: 3881–8. PMID: PMC3137260.

152. Crooke PS, Justenhoven C, Brauch H, the GENICA Consortium, Dawling S, Roodi N, Higginbotham KSP, Plummer WD, Schuyler PA, Sanders ME, Page DL, Smith JR, **Dupont WD**, Parl FF. Estrogen Metabolism and Exposure in a Genotypic-Phenotypic Model for Breast Cancer Risk Prediction. *Cancer Epidemiol Biomarkers Prev*. 2011;**20(7)**: 1502-15. PMPCID: 3472969.
153. Valet RS, Gebretsadik T, Carroll KN, Wu PS, **Dupont WD**, Mitchel EF, Hartert TV. High asthma prevalence and increased morbidity among rural children in a Medicaid cohort. *Ann Allergy Asthma Immunol*. 2011;**106(6)**:467-73. PMID: 21624745.
154. Head DR, Jacobberger JW, Mosse C, Jagasia M, **Dupont W**, Goodman S, Flye L, Shinar A, McClintock-Treep S, Stelzer G, Briggs R, Shults K. Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis. *Bone Marrow Research* 2011; **2011(2011)**:1-9, Article ID 950934. Posted at <http://www.hindawi.com/journals/bmr/2011/950934/>. PMID: PMC3200066.
155. Carroll KN, Gebretsadik T, Larkin EK, **Dupont WD**, Liu Z, Van Driest S, Hartert TV. Relationship of maternal vitamin D level with maternal and infant respiratory disease. *Am J Obstet Gynecol*. 2011; **205(3)**:e1-7. PMID: PMC3171620.
156. Lushnikova T, Bouska A, Odvody J, **Dupont WD**, Eischen CM. Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression. *Oncogene*. 2011;**30(46)**:4622-31. PMID: PMC3161162.
157. Tran T, Barlow B, O'Rear L, Jarvis B, Li ZZ, Dickeson K, **Dupont W**, Zutter M. Loss of the alpha 2 beta 1 Integrin Alters Human Papilloma Virus-Induced Squamous Carcinoma Progression In Vivo and In Vitro. *PLoS One*. 2011;**6(10)**: e26858. PMID: PMC3203166.
158. Mustafa HI, Raj SR, Diedrich A, Black BK, Paranjape SY, **Dupont WD**, Williams GH, Biaggioni I, Robertson D. Altered Systemic Hemodynamic and Baroreflex Response to Angiotensin II in Postural Tachycardia Syndrome. *Circulation-Arrhythmia and Electrophysiology*. 2012;**5(1)**:173-80. PMID: PMC3577936
159. Jules A, Grijalva CG, Zhu YW, Talbot KH, Williams JV, **Dupont WD**, Edwards KM, Schaffner W, Shay DK, Griffin MR. Estimating age-specific influenza-related hospitalization rates during the pandemic (H1N1) 2009 in Davidson Co, TN. *Influenza Other Respi Viruses*. 2012;**6(3)**:e63-e71. PMID: PMC3773818.
160. Carroll KN, Gebretsadik T, Minton P, Woodward K, Liu ZW, Miller EK, Williams JV, **Dupont WD**, Hartert TV. Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. *J Allergy Clin Immunol*. 2012; **129(5)**:1236-42. PMID: PMC3340428.
161. Boulos FI, **Dupont WD**, Schuyler PA, Sanders ME, Page DL, Fedda FA, Simpson JF. Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions. *Cancer*. 2012; **118(9)**:2372-7. PMID: 21918964 Free full text.
162. Fadare O, Parkash V, **Dupont WD**, Acs G, Atkins KA, Irving JA, Pirog EC, Quade BJ, Quddus MR, Rabban JT, Vang R, Hecht JL. The Diagnosis of Endometrial Carcinomas With Clear Cells by Gynecologic Pathologists: An Assessment of Interobserver

- Variability and Associated Morphologic Features. *Am J Surg Pathol*. 2012; **36(8)**:1107-18. PMID: 22790851.
163. Hayes RM, Wu PS, Shelton RC, Cooper WO, **Dupont WD**, Mitchel E, Hartert TV. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. *Am J Obstet Gynecol*. 2012; **207(1)**:e1-9 PMID: PMC3567615.
 164. Wu PS, Carroll KN, Gebretsadik T, **Dupont WD**, Mitchel EF, Hartert TV. The developmental trajectory of pediatric asthma in 3-to-10-year-olds. *J Allergy Clin Immunol*. 2012; **129(5)**:1397-8. PMID: PMC3823550.
 165. Higginbotham KS, Breyer JP, McReynolds KM, Bradley KM, Schuyler PA, Plummer WD, Freudenthal ME, Trentham-Dietz A, Newcomb PA, Parl FF, Sanders ME, Page DL, Egan KM, **Dupont WD**, Smith JR. A Multistage Genetic Association Study Identifies Breast Cancer Risk Loci at 10q25 and 16q24. *Cancer Epidemiol Biomarkers Prev*. 2012; **21(9)**: 1565–73. PMID: PMC3707501.
 166. Breyer JP, Avritt TG, McReynolds KM, **Dupont WD**, Smith JR. Confirmation of the HOXB13 G84E Germline Mutation in Familial Prostate Cancer. *Cancer Epidemiology Biomarkers & Prevention*. 2012; **21(8)**:1348-53. PMID: PMC3415588.
 167. Coffin ST, Black BK, Biaggioni I, Paranjape SY, Orozco C, Black PW, **Dupont WD**, Robertson D, Raj SR. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. *Heart Rhythm*. 2012; **9(9)**:1484-90. PMID: PMC3419341.
 168. Beck WC, Holzman MD, Sharp KW, Nealon WH, **Dupont WD**, Poulouse BK. Comparative Effectiveness of Dynamic Abdominal Sonography for Hernia vs Computed Tomography in the Diagnosis of Incisional Hernia. *J Am Coll Surg*. 2013; **216(3)**:447-53. PMID: 23357727.
 169. Plash WB, Diedrich A, Biaggioni I, Garland EM, Paranjape SY, Black BK, **Dupont WD**, Raj SR. Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics. *Clin Sci*. 2013; **124(1-2)**:109-14. PMID: PMC3478101.
 170. Seegmiller AC, Kim AS, Mosse CA, Levy MA, Thompson MA, Kressin MK, Jagasia MH, Strickland SA, Reddy NM, Marx ER, Sinkfield KJ, Pollard HN, Plummer WD, **Dupont WD**, Shultz EK, Dittus RS, Stead WW, Santoro SA, Zutter MM. Optimizing Personalized Bone Marrow Testing Using an Evidence-Based, Interdisciplinary Team Approach. *Am J Clin Pathol*. November 2013; **140(5)**:643-50. PMID: PMC4159763.
 171. Green EA, Raj V, Shibao CA, Biaggioni I, Black BK, **Dupont WD**, Robertson D, Raj SR. Effects of Norepinephrine Reuptake Inhibition on Postural Tachycardia Syndrome. *Journal of the American Heart Association*. October 2013; **2(5)**: e000395. PMID: PMC3835251.
 172. Miller EK, Gebretsadik T, Carroll KN, **Dupont WD**, Mohamed YA, Morin LL, Heil L, Minton PA, Woodward K, Liu Z, Hartert TV, Williams JV. Viral Etiologies of Infant Bronchiolitis, Croup and Upper Respiratory Illness During 4 Consecutive Years. *Pediatr Infect Dis J*. 2013; **32(9)**:950-5. PMID: PMC3880140.
 173. Mar PL, Raj V, Black BK, Biaggioni I, Shibao CA, Paranjape SY, **Dupont WD**, Robertson D, Raj SR. Acute hemodynamic effects of a selective serotonin reuptake inhibitor in

- postural tachycardia syndrome: A randomized, crossover trial. *J Psychopharmacol (Oxf)*. 2014; **28(2)**:155-61. PMID: PMC3956655.
174. Self WH, Griffin MR, Zhu YW, **Dupont WD**, Barrett TW, Grijalva CG. The high burden of pneumonia on US emergency departments during the 2009 influenza pandemic. *J Infect*. 2014; **68(2)**:156-64. PMID: PMC3947237.
 175. Green EA, Black BK, Biaggioni I, Paranjape SY, Bagai K, Shibao C, Okoye MC, **Dupont WD**, Robertson D, Raj SR. Melatonin reduces tachycardia in postural tachycardia syndrome: a randomized, crossover trial. *Cardiovasc Ther*. 2014; **32(3)**:105-12. PMID: PMC3999238.
 176. Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J, **Dupont WD**, Chelimsky T, Galpern WR. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2014; **13(3)**:268-75. PMID: PMC4030757.
 177. Breyer JP, Dorset DC, Clark TA, Bradley KM, Wahlfors TA, McReynolds KM, Maynard WH, Chang SS, Cookson MS, Smith JA, Schleutker J, **Dupont WD**, Smith JR. An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. *Am J Hum Genet*. 2014; **94(3)**:395-404. PMID: PMC3951923.
 178. Nwazue VC, Arnold AC, Raj V, Black BK, Biaggioni I, Paranjape SY, Orozco C, **Dupont WD**, Robertson D, Raj SR. Understanding the placebo effect in clinical trials for postural tachycardia syndrome. *Clin Exp Pharmacol Physiol*. 2014; **41(5)**:325-30. PMID: PMC4005784.
 179. Nwazue VC, Paranjape SY, Black BK, Biaggioni I, Diedrich A, **Dupont WD**, Robertson D, Raj SR. Postural tachycardia syndrome and inappropriate sinus tachycardia: role of autonomic modulation and sinus node automaticity. *J Am Heart Assoc*. 2014; **3(2)**:e000700. PMID: PMC4187519.
 180. Veeranki SP, Gebretsadik T, Dorris SL, Mitchel EF, Hartert TV, Cooper WO, Tylavsky FA, **Dupont W**, Hartman TJ, Carroll KN. Association of folic acid supplementation during pregnancy and infant bronchiolitis. *Am J Epidemiol*. 2014; **179(8)**:938-46. PMID: PMC3966719.
 181. Kpaeyeh J, Mar PL, Raj V, Black BK, Arnold AC, Biaggioni I, Shibao CA, Paranjape SY, **Dupont WD**, Robertson D, Raj SR. Hemodynamic Profiles and Tolerability of Modafinil in the Treatment of Postural Tachycardia Syndrome A Randomized, Placebo-Controlled Trial. *J Clin Psychopharmacol*. 2014; **34(6)**:738-41. PMID: PMC4239166.
 182. Hartmann LC, Degnim AC, Santen RJ, **Dupont WD**, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. *N Engl J Med*. 2015; **372(1)**:78-89. PMID: PMC4347900.
 183. Sanderson M, O'Hara H, Foderingham N, **Dupont WD**, Shu XO, Peterson N, Fair AM, Disher AC. Type 2 diabetes and mammographic breast density among underserved women. *Cancer Causes Control*. 2015; **26(2)**:303-9. PMID: PMC4301990.

184. Bestawros M, Darbar D, Arain A, Abou-Khalil B, Plummer D, **Dupont WD**, Raj SR. Ictal Asystole and Ictal Syncope Insights Into Clinical Management. *Circulation-Arrhythmia and Electrophysiology*. 2015; **8(1)**:159-64. PMID: PMC4334668.
185. Arnold AC, Haman K, Garland EM, Raj V, **Dupont WD**, Biaggioni I, Robertson D, Raj SR. Cognitive dysfunction in postural tachycardia syndrome. *Clin Sci*. 2015; **128(1)**:39-U52. PMID: PMC4161607.
186. Choi L, Blume JD, **Dupont WD**. Elucidating the Foundations of Statistical Inference with 2 x 2 Tables. *PLoS One*. 2015; **10(4)**:e0121263. PMID: PMC4388855.
187. Gamboa A, Paranjape SY, Black BK, Arnold AC, Figueroa R, Okamoto LE, Nwazue VC, Diedrich A, Plummer WD, **Dupont WD**. Inspiratory Resistance Improves Postural Tachycardia: A Randomized Study. *Circulation: Arrhythmia and Electrophysiology*. 2015:CIRCEP. 114.002605. PMID: PMC4472504.
188. Sanders ME, Schuyler PA, Simpson JF, Page DL, **Dupont WD**. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. *Mod Pathol*. 2015; **28**:662-9. PMID: PMC4416977.
189. Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, et al. Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). *BMC Pulm Med*. 2015;15:45. PMID: PMC4506623.
190. Keck VA, Edgerton DS, Hajizadeh S, Swift LL, **Dupont WD**, Lawrence C, Boyd KL. Effects of Habitat Complexity on Pair-Housed Zebrafish. *J Am Assoc Lab Anim Sci*. 2015; **54(4)**:378-83. PMID: PMC4521571
191. Fair AM, Lewis TJ, Sanderson M, **Dupont WD**, Fletcher S, Egan KM, Disher AC. Increased vitamin D and calcium intake associated with reduced mammographic breast density among premenopausal women. *Nutr Res*. 2015; **35(10)**:851-7. PMID: PMC4579012
192. Celedonio JE, Arnold AC, **Dupont WD**, Ramirez CE, Diedrich A, Okamoto LE, Raj SR, Robertson D, Peltier AC, Biaggioni I, Shibao CA. Residual sympathetic tone is associated with reduced insulin sensitivity in patients with autonomic failure. *Clin Auton Res*. 2015; **25(5)**:309-15. PMID: PMC4785595.
193. Veeranki SP, Gebretsadik T, Mitchel EF, Tylavsky FA, Hartert TV, Cooper WO, **Dupont WD**, Dorris SL, Hartman TJ, Carroll KN. Maternal Folic Acid Supplementation During Pregnancy and Early Childhood Asthma. *Epidemiology*. 2015; **26(6)**:934-41. PMID: PMC4900760
194. Wu P, Feldman AS, Rosas-Salazar C, James K, Escobar G, Gebretsadik T, Li SX, Carroll KN, Walsh E, Mitchel E, Das S, Kumar R, Yu C, **Dupont WD**, Hartert, TV. Relative Importance and Additive Effects of Maternal and Infant Risk Factors on Childhood Asthma. *PLoS One*. 2016; **11(3)**:e0151705. PMID: PMC4803347.
195. Rosado FG, Rinker EB, Plummer W, **Dupont WD**, Spradlin NM, Reichard KK, Kim AS. The diagnosis of adult-onset haemophagocytic lymphohistiocytosis: lessons learned

from a review of 29 cases of bone marrow haemophagocytosis in two large academic institutions. *J Clin Pathol*. 2016;jclinpath-2015-203577.

196. Cook-Mills J, Gebretsadik T, Abdala-Valencia H, Green J, Larkin EK, **Dupont WD**, Shu XO, Gross M, Bai C, Gao Y-T. Interaction of vitamin E isoforms on asthma and allergic airway disease. *Thorax*. 2016:thoraxjnl-2016-208494. Published online PMID: 27257004 PMCID: PMC5278770
197. **Dupont WD**, Blume JD, Smith JR. Building and Validating Complex Models of Breast Cancer Risk. *JAMA Oncol*. 2016; **2(10)**: 1271-1272. PMCID: PMC5278770
198. Degnim AC, **Dupont WD**, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. *Cancer*. 2016; 122(19): 2971-2978. Published online. PMCID: [PMC5030128](#)
199. Cho SH, Min JY, Kim DY, Oh SS, Torgerson DR, Pino-Yanes M, Hu D, Sen S, Huntsman S, Eng C, Farber HJ, Rodriguez-Cintrón W, Rodriguez-Santana JR, Serebrisky D, Thyne SM, Borrell LN, Williams LK, **DuPont W**, Seibold MA, Burchard EG, Avila PC, Kumar R. Association of a PAI-1 Gene Polymorphism and Early Life Infections with Asthma Risk, Exacerbations, and Reduced Lung Function. *PLoS One*. 2016; 11(8):e0157848. PMCID: PMC4996454
200. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, **Dupont WD**, Stein, CM. Association of Proton Pump Inhibitors with Reduced Risk of Warfarin-related Serious Upper Gastrointestinal Bleeding. *Gastroenterology*. 2016; **151(6)**: 1105-1112. PMCID: PMC5124401
201. Carroll KN, Gebretsadik T, Escobar GJ, Wu P, Li SX, Walsh EM, Mitchel E, Sloan CD, **Dupont WD**, Hartert TV. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma. *J Allergy Clin Immunol*. 2017; **139(1)**: 66-71 PMCID: PMC5074917
202. Cates JM, **Dupont WD**. Cytologic anaplasia is a prognostic factor in osteosarcoma biopsies, but mitotic rate or extent of spontaneous tumor necrosis are not: a critique of the College of American Pathologists Bone Biopsy template. *Mod Pathol*. 2017; **30(1)**: 52-59. PMID: 27658478
203. Shaw BH, Garland EM, Black BK, Paranjape SY, Shibao CA, Okamoto LE, Gamboa A, Diedrich A, Plummer WD, **Dupont WD**, Biaggioni I, Robertson D, Raj SR. Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a 'sit-to-stand test'. *J Hypertens*. 2017; **35(5)**: 1019-1025.
204. Reisenbichler ES, **Dupont W**, Plummer WD, Hameed O. Is tumor cellularity in primary invasive breast carcinoma of prognostic significance? *Virchows Arch*. 2017; **470(6)**: 611-617.
205. Lu C, Lewis JS, Jr., **Dupont WD**, Plummer WD, Jr., Janowczyk A, Madabhushi A. An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival. *Mod Pathol*. 2017; 30(12) 1655-1665. PMCID: PMC6128166

206. Lee RL, Brown RF, Gebretsadik T, Hartert TV, **Dupont WD**, Wu P. Alternative Viewpoint: Efficacy and effectiveness of respiratory syncytial virus immunoprophylaxis in children with cystic fibrosis – an unsolved question with more to be asked. *Pharmacotherapy*. 2017; Nov;37(11):e120-e121. doi: 10.1002/phar.2029. Epub 2017 Oct 26. PMID: 28950031.
207. Degnim AC, Winham SJ, Frank RD, Pankratz VS, **Dupont WD**, Vierkant RA, et al. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. *J Clin Oncol*. 2018; **36(18)**:1840-6.
208. Mehrad M, **Dupont WD**, Plummer WD, Jr., Lewis JS, Jr. Expression and Significance of Cytokeratin 7, a Squamocolumnar Junction Marker, in Head and Neck Squamous Cell Carcinoma. *Head Neck Pathol*. 2018 Dec;**12(4)**:448-454. doi: 10.1007/s12105-017-0874-2. Epub 2017 Dec 12. PMCID: PMC6232215.
209. Blume JD, D'Agostino McGowan L, **Dupont WD**, Greevy RA, Jr. Second-generation p-values: Improved rigor, reproducibility, & transparency in statistical analyses. *PLoS One*. 2018;13(3):e0188299. PMCID: PMC5863943.
210. Parl FF, Crooke PS, Plummer WD, **Dupont WD**. Genomic-Epidemiologic Evidence that Estrogens Promote Breast Cancer Development. *Cancer Epidemiol Biomarkers Prev*. 2018; **27(8)**: 899-907 5 PMCID: PMC6072561
- 88th Breast Cancer publication**
- Wu P, Escobar GJ, Gebretsadik T, Carroll KN, Li SX, Walsh EM, Mitchel EF, Sloan C, **Dupont WD**, Yu C, Horner JR, Hartert TV. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis on Bronchiolitis Hospitalizations among High-risk Infants. *Am J Epidemiol*. 2018; **187(7)**: 1490-1500. PMCID: PMC6030843
211. Chung CP, Callahan ST, Cooper WO, **Dupont WD**, Murray KT, Franklin AD, Hall K, Dudley JA, Stein CM, Ray WA. Outpatient Opioid Prescriptions for Children and Opioid-Related Adverse Events. *Pediatrics*. 2018; 142(2): e20172156. pii: e20172156. doi: 10.1542/peds.2017-2156. Epub 2018 Jul 16. PMCID: PMC6072590.
212. Chung CP, **Dupont WD**, Murray KT, Hall K, Michael Stein C, Ray WA. Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study. *Pharmacoepidemiol Drug Saf*. 2018; Jul 12. doi: 10.1002/pds.4619. [Epub ahead of print]. PMCID: PMC6330158.
213. Patrick SW, Buntin MB, Martin PR, Scott TA, **Dupont W**, Richards M, et al. Barriers to Accessing Treatment for Pregnant Women with Opioid Use Disorder in Appalachian States. *Subst Abus*. 2018; Jun 27:1–7. <https://doi.org/10.1080/08897077.2018.1488336>
214. Riddell CA, Bhat N, Bont LJ, **Dupont WD**, Feikin DR, Fell DB, et al. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis. *Vaccine*. 2018; **36(52)**:8100-9. PMCID: PMC6288067.
215. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, **Dupont WD**, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. *JAMA*. 2018; **320(21)**:2221-30. PMCID: PMC6404233.

216. Nian H, Yu C, Ding J, Wu H, **Dupont WD**, Brunwasser S, et al. Performance evaluation of propensity score methods for estimating average treatment effects with multi-level treatments. *Journal of Applied Statistics*. 2019; **46(5)**:853-73.
217. Kovach AE, Moulton DE, Plummer Jr WD, **Dupont WD**, Pacheco MC. Correlation of Endoscopic and Histologic Severity Scores in Pediatric Ulcerative Colitis at First Presentation. *Pediatr Dev Pathol*. 2019 Mar-Apr; **22(2)**:106-111. doi: 10.1177/1093526618803736. Epub 2018 Oct 9. PMID: 30301443
218. Vereen S, Gebretsadik T, Johnson N, Hartman TJ, Veeranki SP, Piyathilake C, Mitchel EF, Kocak M, Cooper WO, **Dupont WD**, Tylavsky F, Carroll KN. Association Between Maternal 2nd Trimester Plasma Folate Levels and Infant Bronchiolitis. *Matern Child Health J*. 2019; **23(2)**:164-72. PMID: PMC6339607.
219. Gandelman JS, Khan OA, Shuey MM, Neal JE, McNeer E, Dickson A, Barnado A, Wang L, Anandi P, **Dupont WD**, Stein CM, Chung CP Increased Incidence of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study. *Arthritis Care Res* . 2019. Mar 15. doi: 10.1002/acr.23880. [Epub ahead of print]
220. Darbyshire AK, Oliver KH, **Dupont WD**, Plummer WD, Jones CP, Boyd KL. Anesthesia and Euthanasia of Brine Shrimp (*Artemia franciscana*). *J Am Assoc Lab Anim Sci*. 2019; **58(1)**:58-64.
221. Chung CP, **Dupont WD**, Murray KT, Hall K, Stein CM, Ray WA. Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study. *Pharmacoepidemiol Drug Saf*. 2019;28(1):48-53. PMID: PMC6330158.
222. Chung CP, Callahan ST, Cooper WO, **Dupont WD**, Murray KT, Franklin AD, Hall K, Dudley JA, Stein CM, Ray WA Outpatient opioid prescriptions for children and opioid-related adverse events. *Pediatrics*. 2018;**142(2)**:e20172156. PMID: PMC6072590.
223. Blume JD, Greevy RA, Welty VF, Smith JR, **Dupont WD**. An Introduction to Second-Generation p-Values. *Am Stat*. 2019;**73(sup1)**:157-67.

Books

1. **Dupont WD**: *Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data*. Cambridge U.K.: Cambridge University Press, 2002: 2nd printing 2003.
2. **Dupont WD**: *Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data. 2nd Edition*. Cambridge U.K.: Cambridge University Press, 2009. See also <http://biostat.mc.vanderbilt.edu/dupontwd/wddtext/index.html> and <http://www.cambridge.org/us/catalogue/catalogue.asp?isbn=9780521614801>

Book Chapters

1. **Dupont WD** and Page DL: Histologic predictors of breast cancer: Epidemiologic and statistical aspects. In: Ames FC, Blumenschein GR, Montague ED, eds. *Current Controversies in Breast Cancer*, Austin: University of Texas Press, 1984:51-61.

2. **Dupont WD** and Page DL: Relationship to previous breast disease. In: Stoll B.A., ed. *Women at High Risk to Breast Cancer*, Dordrecht, The Netherlands: Kluwer Academic Publishers, 1989:47-56.
3. **Dupont WD** and Page DL: Histo-pathologic definition of high risk breast lesions. In: Bigot JM, Moreau JF, Nahum H, Bellet M, eds. *Radiology*, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1989:339-44.
4. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, 1991:292-8.
5. Page DL and **Dupont WD**: Management of the patient at high risk. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, 1991:1046-52.
6. Page DL, **Dupont WD** and Rodgers W: Concepts of preneoplasia for the goal of cancer prevention. In: *Control of Growth Factors and Prevention of Cancer*, Berlin: Springer-Verlag, 1992:3-11.
7. **Dupont WD** and Page DL: An overview of the effect of oestrogen replacement therapy on breast cancer risk. In: Mann RD, ed. *Hormonal Replacement Therapy and Breast Cancer Risk*, Park Ridge, NJ: Parthenon Publishing, 1992:79-92.
8. Page DL and **Dupont WD**: Estrogen replacement therapy and breast cancer risk. In: Ioannidou-Mouzaka L, Agantis NJ and Karydas I, eds. *Senology, Proceedings of the 7th International Congress on Senology (Breast Diseases), Island of Rhodes, Greece, 3-7 May 1992*, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1992:41-4.
9. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, Second Edition, 1998: 427-34.
10. Page DL, Caro SW, and **Dupont WD**: Management of the patient at high risk. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, Second Edition, 1998: 1453-9.
11. Page DL, Rogers LW, Schuyler PA, **Dupont WD**, and Jensen RA: The natural history of ductal carcinoma in situ of the breast. In: Silverstein MJ, ed. *Ductal Carcinoma in Situ of the Breast*, Philadelphia: Lippincott Williams and Wilkins, Second Edition, 2002:17-21.
12. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Disorders*, Philadelphia: W.B. Saunders, Third Edition, Vol. 1. 2004: 469-478.
13. Caro SW, Page DL, and **Dupont WD**: Management of the patient at high risk. In: Bland KI and Copeland EM, eds. *The Breast; Comprehensive Management of Benign and Malignant Disorders*, Philadelphia: W.B. Saunders, Third Edition, Vol. 2. 2004: 1499-1510.

14. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Disorders*, Philadelphia: Saunders Elsevier, Fourth Edition, Vol. 1. 2009: 477-484.
15. **Dupont WD** Degnim AC, Sanders ME, Simpson JF, Hartmann LC: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Disorders*, Philadelphia: Elsevier, Fifth Edition. 2018: 264-271.

Letters to the Editor

1. **Dupont WD**: Making causal inferences from observational data, *Biometrics*, December 1978; 34:713-14.
2. **Dupont WD**: Case-control studies of estrogens and endometrial cancer, *N Engl J Med*, March 1979; 300:495.
3. **Dupont WD**: Bias, maximum likelihood estimators, and sequential clinical trials, *Controlled Clin Trials*, September 1984; 5:275-7.
4. **Dupont WD** and Page DL: Fibrocystic breast non-disease, *N Engl J Med*, 1985; 312:1258.
5. **Dupont W**, Page D: A retrospective cohort study of women with benign breast disease - interactions between histologic and other factors on breast-cancer risk, *Am J Epidemiol* 1985; 122 (3): 516-516.
6. **Dupont WD**: Randomized vs. historical trials: are the benefits worth the cost? *Am J Epidemiol*, August 1986; 124:340-1.
7. **Dupont W**, Page D: Influence of exogenous estrogens and proliferative breast disease on breast-cancer risk, *Am J Epidemiol*, 1987; 126 (4): 735
8. **Dupont WD**: The EC-IC bypass study, *N Engl J Med*, October 1987; 317:1031.
9. **Dupont WD**: Sensitivity of Fisher's exact test to minor perturbations in 2x2 contingency tables — Author's Reply, *Stat Med*, 1989; 8:244-5.
10. **Dupont WD** and Page DL: Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk — Author's Reply, *Cancer*, 1990; 65:1261-2.
11. **Dupont WD**: Growth hormone for the elderly, *N Engl J Med*, 1990; 323:1562.
12. **Dupont WD**: Estrogen replacement therapy and risk of breast cancer, *JAMA*, 1991; 265:1824.
13. **Dupont WD** and Page DL: Estrogen and breast cancer — Author's reply, *Arch Intern Med*, 1991; 151:1882-4.
14. **Dupont WD** and Page DL: Meta-analyses of breast cancer risk associated with estrogen replacement therapy — Author's reply, *Arch Intern Med*, 1992; 152:1090-3.

15. **Dupont WD**: The breast implant controversy, *N Engl J Med*, 1993; 328:733.
16. **Dupont WD**: Breast cancer and hormone-replacement therapy, *N Engl J. Med*, 1995; 333:1356-8.
17. **Dupont WD**: Comparison of ganisetron, onansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. *Cancer*, 1996; 78:2451.
18. **Dupont WD** and Plummer WD: PS power and sample size program available for free on the Internet. *Controlled Clin Trials*,1997;18:274.
19. Edwards KM and **Dupont WD**: Intranasal Influenzavirus Vaccine in Children. *N Engl J Med*, 1998; 339:922.
20. Wu PS, **Dupont WD**, Griffin MR, Hartert, TV. The Roles of Vitamin D, Temperature, and Viral Infections in Seasonal Risk of Acquiring Asthma – From the Authors. *Am J Respir Crit Care Med*. 2009; 179(11): 1072-1073. PMID: 20053969.
21. Hartmann LC, Degenim AC, **Dupont WD**: Atypical Hyperplasia of the Breast REPLY. *N Engl J Med*. 2015; **372(13)**:1271-2.
22. Degenim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD, Winham SJ, Vachon CM, **Dupont WD**, Hartmann LC. Breast cancer risk by the extent and type of atypical hyperplasia. *Cancer*. 2016; **122(19)**:3087-3088. PMCID: In progress
23. Gebretsadik T, Wu P, Carroll KN, **Dupont WD**, Hartert TV. Preventing RSV: Preventing Asthma—The Missing Link. *Am J Respir Crit Care Med*. 2017; **196(1)**:116-117. PMCID: In progress.
24. **Dupont W**, Wu P, Gebretsadik T, Hartert T. RSV prevention in infancy and asthma in later life. *Lancet Respir Med*. 2018;6(7):e32.

Book Reviews

1. **Dupont WD**: *Statistical Methods in Medical Research* . 3rd edition. by P. Armitage and G. Berry. Reviewed in *Circulation*, 1996; 94: 3009-10.
2. **Dupont WD**: *A Handbook of Statistical Analyses Using Stata, Fourth Edition*, by S. Rabe-Hesketh and B.S. Everitt. Reviewed in *The Stata Journal* 2007; 7:245-248.
3. **Dupont WD**: *Multivariable Model-building: A pragmatic approach to regression analysis based on fractional polynomials for modeling continuous variables*. by P. Royston & W. Sauerbrei. Reviewed in *The Stata Journal*, 2010; 10(2):297-302 .

Theses and Student Papers

1. **Dupont WD**: An adaptive automatic integration algorithm based on Simpson's rule, M.Sc. thesis, McGill University, 1971.
2. **Dupont WD**: A multiple risk model with dependent fates, Technical Paper #501, Biostatistics Department, The Johns Hopkins University, 1975.

3. **Dupont WD:** A stochastic method for estimating animal abundance from catch-effort data, Ph.D. Thesis, The Johns Hopkins University, 1976.

National Television

1. Fibroadenoma and breast cancer
 - i) NBC Nightly News, July 6, 1994
 - ii) CBS Evening News, July 6, 1994
 - iii) CBS This Morning, July 7, 1994
 - iv) CNN News from Medicine, July 7, 1994

Other Publications

1. **Dupont WD:** A hazard regression method for estimating animal abundance from catch-effort data. *American Statistical Association, 1981 Proceedings of the Statistical Computing Section*, Washington: American Statistical Association, August 1981:45-52.
2. **Dupont WD**, Wright RF, and Plummer WD: *Update: An Interactive Data Entry and Edit Program*. Nashville: CDM Software, 1981:1-102.
3. **Dupont WD** and Plummer WD: CDM: Clinical data management software for interactive data entry and data quality assurance. (New Developments in Statistical Computing) *The American Statistician*, 1985; 39:211.
4. Consensus Meeting, October 3 – 5, 1985, New York: Convened by the Cancer Committee of the College of American Pathologists (**Dupont WD**, participant): Is 'fibrocystic disease' of the breast precancerous? *Arch Pathol Lab Med*, 1986; 110:171-3.
5. **Dupont WD** and Plummer WD: POWER.FOR: A computer program for power and sample size calculations. (New Developments in Statistical Computing) *The American Statistician*, 1991; 45:158.
6. International Medical Benefit/Risk Foundation Workshop (London, October 29 – 30, 1992, **Dupont WD**, participant) Hormone replacement therapy (HRT) and breast cancer risk. *Pharmacoepidemiology and Drug Safety*, 1993; 2:103-5.
7. International Medical Benefit/Risk Foundation (**Dupont WD**, Participant) Workshop on hormone replacement therapy and breast cancer risk — future studies. (Chairman: Professor S. Shapiro) *Pharmacoepidemiology and Drug Safety*, 1993; 2:557-8.
8. Bernard GR, Wheeler AP, Arons MM, Morris PE, Ray HL, Russell JA, Wright PE, and the Antioxidant in ARDS Study Group: A trial of antioxidants N-acetylcysteine and procysteine in the acute respiratory distress syndrome. *Chest*, 1997; 112: 164-72.
9. **Dupont WD:** Teaching intermediate-level biostatistics to clinicians using general statistical software packages. *2004 ASA Proceedings*. Alexandria VA: American Statistical Association 2005:4720-1.

Presentations at Scientific Meetings

1. **Dupont WD:** Estimating animal abundance from catch-effort data. Eastern Regional Meetings of the American Statistical Association, Chapel Hill, NC, April 1977.

2. **Dupont WD**: Comparing low mortality rates in longitudinal censored observational data. Joint Statistical Meetings of the American Statistical Association and the Biometric Society, Washington, DC, August 1979. *Biometrics*, 1980; 36:736.
3. **Dupont WD**: Choosing the best P value for clinical trials. Society for Clinical Trials, Philadelphia, PA, May 1980. *Controlled Clin Trials*, 1980; 1:171.
4. **Dupont WD** and Wright RF: An interactive data quality assurance program. Society for Clinical Trials, San Francisco, CA, May 1981. *Controlled Clin Trials*, 1981; 2:81.
5. **Dupont WD**: A hazard regression method for estimating animal abundance from catch-effort data, (an invited paper). Joint Statistical Meetings of the American Statistical Association and the Biometric Society, Detroit, MI, August 1981.
6. **Dupont WD**: Fisher's exact test and the magically shrinking P-value. Joint Statistical Meetings of the American Statistical Association and the Biometric Society, Detroit, MI, August 1981.
7. **Dupont WD**, Wright RF, and Plummer WD: A sequential log rank test. Society for Clinical Trials, Pittsburgh, PA, May 1982. *Controlled Clin Trials*, 1982; 3:139.
8. **Dupont WD** and Page DL: Histologic predictors of breast cancer: epidemiologic and statistical aspects, (an invited paper). 26th Annual Clinical Conference of the University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX, November 1982.
9. **Dupont WD** and Page DL: A retrospective cohort study of women with benign breast disease: Interactions between histologic and other factors on breast cancer risk. Society for Epidemiologic Research, Chapel Hill, NC, June 1985. *Am J Epidemiol*, 1985; 122:516.
10. **Dupont WD**: Epidemiology of benign breast lesions and the risk for cancer (an invited paper). Conference sponsored by the College of American Pathologists entitled Is 'Fibrocystic Disease' of the Breast Precancerous? New York, NY, October 1985.
11. **Dupont WD**: Converting relative risks to absolute risks: a graphical approach for breast cancer and heart disease. Society for Clinical Trials, Montreal, QC, May 1986. *Controlled Clin Trials*, 1986; 7:238.
12. Antman E, Califf RM, Danforth JW, **Dupont WD**, and other panel discussants, L.I.M.I.T./Supplemental U.S. Trials. Symposium on the Treatment of Acute Myocardial Infarction sponsored by CIBA-GEIGY Corporation, Maui, HI, September 1986.
13. **Dupont WD** and Page DL: Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. Society for Epidemiologic Research, Amherst, MA, June 1987. *Am J Epidemiol*, 1987; 126:735.
14. **Dupont WD** and Page DL: Determining precursor lesions for human cancers: A methodologic overview, (an invited paper). Society for Epidemiologic Research. Vancouver, BC, June 1988. *Am J Epidemiol*, 1988; 128:945.
15. **Dupont WD**, Page DL, Parl FF, Rados MA, and Plummer WD: Breast cancer risk associated with fibroadenomas. Society for Epidemiologic Research, Vancouver, BC, June 1988. *Am J Epidemiol*, 1988; 128:914, *Laboratory Investigation*, 1990; 62:28A.

16. **Dupont WD:** Power calculations for matched case-control studies. Joint Statistical Meetings. New Orleans, LA, August 1988.
17. **Dupont WD** and Page DL: Implications of high-risk pathologic lesions of the breast, (an invited paper). 74th Clinical Congress of the American College of Surgeons, Chicago, IL, October 1988.
18. **Dupont WD:** Statistical inference from sequentially monitored clinical trials, (an invited paper). Third Annual Symposium of the International Institute for Theoretical Cardiology, Greenville, NC, November 1988.
19. **Dupont WD** and Page DL: Histopathologic definition of high risk breast lesions, (an invited paper). Seventeenth International Congress of Radiology, Paris, France, July 1989.
20. **Dupont WD** and Page DL: Does replacement estrogen therapy increase breast cancer risk? (an invited paper). 17^{es} Journées Sur La Fertilité et L'Orthogénie, Paris, France, November 1989.
21. **Dupont WD** and Page DL: What are the frontiers of research in benign breast disease? (an invited paper). 17^{es} Journées Sur La Fertilité et L'Orthogénie, Paris, France, November 1989.
22. **Dupont WD** and Plummer WD: Power and sample size calculations: A review and computer program, Eleventh Annual Meeting of The Society for Clinical Trials, Toronto, ON, May, 1990. *Controlled Clin Trials*, 1990; 11:301.
23. **Dupont WD:** Statistical issues in assessing prognostic indices for breast cancer, (an invited paper). The American Joint Committee on Cancer, Chicago, IL, June 1990.
24. **Dupont WD** and Page DL: Breast cancer risk, family history, and epithelial hyperplasia. 15th International Cancer Congress, Hamburg, Germany, August 1990.
25. Page DL, **Dupont WD**, and other discussants. Breakout sessions on the limits of early detection of breast cancer, the definitions of precancerous breast lesions, the effects of tamoxifen on high risk lesions, and the incidence of premalignant lesions. NCI workshop on Emerging Concepts and Strategies in Breast Cancer, St. Michaels, MD, September 1990.
26. **Dupont WD:** Breast cancer risk associated with estrogen replacement therapy. Presentation made to the FDA Fertility and Maternal Health Drugs Advisory Committee, Washington, DC, June 1991.
27. **Dupont WD** and Page DL: Hormone replacement therapy and breast cancer, (an invited paper). Symposium on hormone replacement therapy sponsored by the Royal Medical Society. London, England, September 1991.
28. **Dupont WD:** Benign high-risk and premalignant diseases of the breast, (an invited paper). Clinical Congress of the American College of Surgeons, Chicago, IL, October 1991.
29. **Dupont WD:** Epidemiology of benign breast disease and risk factors for breast cancer, (an invited paper). Quartrième Journée Scientifique: Collège de Gynécologie Médicale de Paris — Ile-de-France, Paris, France, January 1992.

30. **Dupont WD:** Benign proliferative diseases of the breast: Histologic definitions and breast cancer risks, (an invited paper). International Course of Diagnostic Imaging and Interventional Radiology (CARVAT), Rome, Italy, January 1992.
31. **Dupont WD:** Estrogen replacement therapy and breast cancer risk in women with a history of benign mammary dysplasia, (an invited paper). International Course of Diagnostic Imaging and Interventional Radiology (CARVAT), Rome, Italy, January 1992.
32. **Dupont WD:** Premalignant markers of increased breast cancer risk, (an invited paper). 83rd Annual Meeting of the American Association for Cancer Research, San Diego, CA, May 1992.
33. **Dupont WD, Parl FF, Hartmann WH, and Brinton LA:** Breast cancer risk associated with proliferative breast disease. 25th Annual Meeting for the Society for Epidemiologic Research. Minneapolis, MN, June 1992. *Am J Epidemiol*, 1992; 136:964.
34. **Dupont WD** (an invited participant): Workshop on HRT and breast cancer risk: International Medical Benefit Risk Foundation. London, England, 1992.
35. **Dupont WD:** Premalignant markers of increased breast cancer risk, (an invited paper). Gordon Research Conference on Mammary Gland Biology. New London NH, June 1993. *Science*, 1993; 259:1190.
36. **Dupont WD and Page DL:** Epidemiology of benign breast disease and risk factors for breast cancer, (an invited paper). American Cancer Society: National Conference on Breast Cancer. Boston, MA, August 1993.
37. **Dupont WD:** HRT and breast cancer. Wyeth-Ayerst MCS and Regional Clinical Associates Meeting. Frazer, PA, October 1993.
38. **Dupont WD:** Breast Cancer: Who's at risk? Wyeth-Ayerst Women's Health Seminar. Princeton, NJ, November 1993.
39. **Dupont WD:** Premalignant markers of breast cancer risk. (Invited plenary address Conférence du Président) Symposium International de Biologie et Pathologie du Tissu Mammaire. Paris, France, December 1993.
40. **Dupont WD:** HRT and breast cancer. Wyeth-Ayerst International Symposium on Contemporary Approaches to Managing Estrogen Deficiency. Santiago, Chile, April 1994.
41. **Dupont WD.** Oral HRT and breast cancer. Laboratoire Innothera Workshop: THS per os: contre-indications? Paris, France, September 1994.
42. **Dupont WD.** Estrogen replacement therapy after breast cancer. (an invited paper). XIV World Congress of the International Federation of Gynecology and Obstetrics. Montreal, Canada, September 1994.
43. **Dupont WD.** Hormones and breast cancer, (an invited paper). Xi^e Journées: Actualités en Gynécologie-Obstétrique. Collège de Gynécologie Médicale du Sud-Est. Nice, France, February 1995.
44. **Dupont WD.** Hormones et cancer, (an invited paper). Le Collège de Gynécologie Rhône-Alpes. Lyon, France, February 1995.

45. **Dupont WD.** Hormonal replacement therapy and breast cancer risk, (an invited paper). National Consortium of Breast Centers. Nashville, TN, April 1995.
46. **Dupont WD.** Breast cancer risk associated with complex and non-complex fibroadenoma, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
47. **Dupont WD.** Breast cancer risk associated with proliferative breast disease and atypical hyperplasia, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
48. **Dupont WD.** Breast Cancer risk associated with long-term hormone replacement therapy, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
49. **Dupont WD.** Hormonal replacement therapy after breast cancer: Arguments in favor of clinical studies, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
50. **Dupont WD.** Benefits and risks of HRT with cyclic or continuous regimes: The breast cancer risk controversy, (an invited paper). Wyeth-Ayerst symposium on Individualized HRT with Cyclic or Continuous Regimes. European Consensus Development Conference on Menopause. Montreux, Switzerland, September 1995.
51. **Dupont WD.** Epidemiologic and Biostatistical Methods. Part I - Introduction. National Breast Cancer Coalition. Project LEAD. Nashville, TN, December 1995.
52. **Dupont WD.** Epidemiologic and Biostatistical Methods. Part III -Clinical Trials. National Breast Cancer Coalition. Project LEAD. Nashville, TN, December 1995.
53. **Dupont WD.** Hormonal replacement therapy and breast cancer risk. Cancer Institute of New Jersey (an invited paper in the Institute's Distinguished Lecture Series) New Brunswick, NJ, October 1996.
54. **Dupont WD.** Hormone replacement therapy and the risk of breast cancer. 14th Annual International Breast Cancer Conference. Miami Beach, FL, 1997.
55. **Dupont WD.** Controversies in hormonal replacement therapy 21st Central American Congress of Obstetrics and Gynecology. Managua, Nicaragua, 1997.
56. **Dupont WD.** Hormonal replacement therapy in patients with breast cancer 21st Central American Congress of Obstetrics and Gynecology. Managua, Nicaragua, 1997.
57. **Dupont WD.** Le THS chez la femme à risque de cancer du sein. 20th meeting of the Association Française pour l'Étude de la Ménopause. Paris, France, November 1999.
58. **Dupont WD.** Incidence of breast cancer in high risk patients receiving HRT. RAP-Risk and Prevention Conference. Paris, France, February 2000.
59. **Dupont WD, Plummer WD.** The PS Program for Sample Size and Power Calculations. JSM 2001. Atlanta, Georgia, USA, August 5, 2001.
60. **Dupont WD, Plummer WD.** Density distribution sunflower plots. JSM 2003. San Francisco, California, USA, August 2003.

61. **Dupont WD.** TGF- β 1 T29 \rightarrow C polymorphism and breast cancer risk in women with and without proliferative disease. N.C.I. Breast SPORE Roundtable Meeting. Boston, MA, November 2003.
62. Gobbi H, **Dupont WD**, Parl FF, Schuyler PA, Plummer WD, Olson SJ, Page DL: Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia. 12th SPORE Investigator's Workshop. Baltimore, MD, July, 2004.
63. **Dupont WD.** Teaching Intermediate-level biostatistics to clinicians using general statistical software packages. Section on Teaching of Statistics in the Health Sciences Round Table Luncheon. Joint Statistical Meetings, Toronto, Ontario, Canada, August 2004.
64. **Dupont WD.** Density distribution sunflower plots in Stata 8. Third North American Stata Users Group Meeting. Boston, MA. August 2004.
65. Sanders ME, Parl FF, Page DL, Roodi N, Schuyler PA, Plummer WD, **Dupont WD:** Relationship of the transformation growth factor- β 1 T29 \rightarrow C polymorphism to breast cancer risk in women with, and without, proliferative breast disease. San Antonio Breast Cancer Symposium, December 2004. *Breast Cancer Research and Treatment* 2004; 88: S162.
66. Breyer J, Schuyler P, Elmore B, Yaspan B, Bradley K, Page D, **Dupont W**, Smith J: Genetic data from archival tissue. 14th SPORE Investigators' Workshop. July 2006.
67. **Dupont WD**, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Sanders ME, Page DL, Smith JR. Effect of protein phosphatase 2A subunit gene haplotype and proliferative breast disease on breast cancer risk. San Antonio Breast Cancer Symposium, December 2008. *Cancer Res* 2009;69 (2 Suppl.): 229S
68. **Dupont WD.** Relative and absolute risks: Explaining the practical implications of research findings to patients and clinicians. Personalized Risk Prediction Symposium. Vanderbilt University, April 2013.
69. **Dupont WD.** Elucidating the Foundations of Statistical Inference with 2 x 2 Tables. Charles Rohde Symposium. Johns Hopkins Bloomberg School of Public Health. Department of Biostatistics. April 2015. <https://youtu.be/w9BadqkuUS0>

Papers Citing Publications by W. D. Dupont

The following graph was created by the *Google Scholar* on April 12, 2019. It shows the number of times papers by W. D. Dupont and colleagues were cited in the literature by year of publication of the papers that cite his work (years prior to 1988 are not shown). On this date, there were a total of 25,615 academic publications that had cited his work. His *h*-index was 70 and 173 of his publications had been cited 10 or more times. Dupont and Page (*N Engl J Med*, 1985; 312:146-51), Ritchie et al. (*Am J Hum Genet*, 2001;69:138-47), and Dupont and Plummer (*Controlled Clin Trials*, 1990; 11:116-28) have been cited 2088, 1811 and 1704 times, respectively. For additional details, search for *dupont wd google scholar citations*.

